Interpreting Biological Similarity: Ongoing Challenges for Diverse Decision Makers by Cork, Sarah M.
Michigan Telecommunications and Technology Law Review
Volume 19 | Issue 2
2013
Interpreting Biological Similarity: Ongoing
Challenges for Diverse Decision Makers
Sarah M. Cork
University of Michigan Law School
Follow this and additional works at: http://repository.law.umich.edu/mttlr
Part of the Administrative Law Commons, Food and Drug Law Commons, Intellectual Property
Law Commons, and the Legislation Commons
This Note is brought to you for free and open access by the Journals at University of Michigan Law School Scholarship Repository. It has been accepted
for inclusion in Michigan Telecommunications and Technology Law Review by an authorized editor of University of Michigan Law School Scholarship
Repository. For more information, please contact mlaw.repository@umich.edu.
Recommended Citation
Sarah M. Cork, Interpreting Biological Similarity: Ongoing Challenges for Diverse Decision Makers, 19 Mich. Telecomm. & Tech. L.
Rev. 423 (2013).
Available at: http://repository.law.umich.edu/mttlr/vol19/iss2/4
NOTE
INTERPRETING BIOLOGICAL SIMILARITY:
ONGOING CHALLENGES FOR DIVERSE
DECISION MAKERS
Sarah M. Cork*
Cite as: Sarah M. Cork, Interpreting Biological Similarity:
Ongoing Challenges for Diverse Decision Makers,
19 MIcH. TELECOMM. & TECH. L. REV. 423 (2012),
available at http://www.mttlr.org/volnineteen/cork.pdf
Similarity is an elusive and complicated concept facing comparisons of
biological molecules, as even minute changes to a molecule's structure
can dramatically affect its function in the body. Yet the flood of bio-
logic drugs on the market will increasingly force these similarity com-
parisons. These concerns are particularly relevant to two groups of
drugs: families of biologic drugs that closely resemble each other in
structure and function, here termed "similar-impact biologics," and
the biosimilars, which are intended to closely approximate generic
forms of biologic drugs. In bringing biologic drugs to the market, man-
ufacturers are likely to face dual obstacles: FDA approval and patent
protection. These hurdles are somewhat in tension with each other. The
more similar biosimilars are to their pioneer counterparts, the more
easily they may advance to market via the Biologics Price Competition
and Innovation Act's ("BPCIA") new accelerated approval pathway.
While the FDA has provided some guidance about how much similarity
is likely to suffice, the standard is not yet clearly defined. In contrast,
the more similar two drugs are to one another, the less likely that they
will be able to obtain patent protection. Further, biologic drugs pose
special issues when considering various legal factors required for pat-
entability. Resolving these questions for the optimal benefit of all stake-
holders requires both fundamental institutional competency and a
willingness on the part of decision makers to engage with difficult sci-
entific questions. This Note explores these ongoing challenges, with
particular focus on the clinical and litigation history of the TNFd in-
hibitors Humira, Enbrel, and Remicade.
* B.S., Duke University (2005); Ph.D., Neuroscience, Emory University (2011); J.D.
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INTRODUCTION
The degree to which two molecules resemble each other can have signif-
icant legal and regulatory consequences. Yet defining these boundaries is no
easy feat, given the complexity of the subject matter. When faced with the
question of defining similarity, choosing the right word for the task can be
problematic and is likely to depend on the speaker's identity. For example,
Congress and the Food and Drug Administration ("FDA") define "drug" one
way in the Federal Food and Drug Cosmetic Act ("FDCA"),' while medical
professionals employ looser terminology. 2
1. See 21 U.S.C. § 321(g)(1) (2011) ("The term 'drug' means (A) articles recognized
in the official United States Pharmacopceia, official Homa opathic Pharmacopoeia of the
United States, or official National Formulary, or any supplement to any of them; and (B)
articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease
in man or other animals; and (C) articles (other than food) intended to affect the structure or
any function of the body of man or other animals; and (D) articles intended for use as a
component of any article specified in clause (A), (B), or (C).").
2. E.g., Definition: Drug, MEDILEXICON, http://www.medilexicon.com/medicaldiction
ary.php?t=26719 (last visited Feb. 2, 2013) (defining "drug" as a "[tiherapeutic agent; any
substance, other than food, used in the prevention, diagnosis, alleviation, treatment, or cure of
disease").
Interpreting Biological Similarity
If asked to define "drug," an ordinary layperson might instinctively try
to describe a class of chemicals which I refer to as "small-molecule drugs,"
and which fall within the FDCA's definition. In this context, "small" means
that the drug's structure comprises a relatively limited number of atoms,'
with the result that small-molecule drugs have low molecular weight.4 Labo-
ratories can create small-molecule drugs using standard chemical synthesis
protocols. The standardization of these protocols makes it relatively easy for
other manufacturers to replicate generic, essentially identical versions of
small-molecule drugs.5
Although small-molecule drugs are perhaps the most familiar type of
drugs, a new class of drugs is becoming quite prominent in the market and in
the practice of medicine. In recent years, pharmaceutical companies have
invested significantly in developing biologics, or drugs based on molecules
and proteins in our own bodies.6 Scholars have long noted this trend,7 and,
with the recent passage of the BPCIA, it is only expected to continue. One
study predicts that by 2015, nearly half of new drug approvals will be bio-
logics., These drugs represent a significant investment on the part of manu-
facturers. Due to their complexity, manufacture of these drugs is
complicated and development is quite expensive: one estimate places re-
search and development costs for a single biologic drug at $1.24-$1.33 bil-
lion.9 Developing biologics is thus no trivial endeavor, given the steep rates
3. See, e.g., Small Molecule Versus Biological Drugs, GENERICS & BIOSIMILARS INrn-
ATIVIE (June 29, 2012), http://www.gabionline.net/Biosimilars/Research/Small-molecule-ver
sus-biological-drugs (illustrating this principle with the familiar example of aspirin, which is
composed of only twenty-one atoms).
4. Id.
5. Id.
6. E.g., Kevin Grogan, Pharma Patent Filings Fall amid Shift to Biologics, PHARMA
TIMES (Mar. 21, 2012), http://www.pharmatimes.com/article/12-03-21/Pharma patent filings
fallamidshiftjtobiologics.aspx. But see Drug Discovery 2.0: Rise of the Biosimilar? Not So
Fast, CURIOUS WAVoEUNCTION (Aug. 22, 2012), http://wavefunction.fieldofscience.com/2012/
08/will-biologics-supersede-small.htmI ("[R]umors of small molecules' deaths are grossly
exaggerated.").
7. Bryan A. Liang, Regulating Follow-on Biologics, 44 HARV. J. ON LEGIs. 363,
363-64 (2007) ("[S]ales of biologics have grown ... rapidly, with an increase of seventeen
percent in 2005 and annual expenditures worldwide of greater than $50 billion. By 2010,
spending on biologics is estimated to grow to $105 billion, with biologics making up nearly
half of all newly approved medicines.").
8. Berkowitz et al., Analytical Tools for Characterizing Biopharmaceuticals and the
Implications for Biosimilars, II NATURE Rieinws DRUG DISCOVERY 527, 527 (2012) (also
predicting an increase to 70% by 2025).
9. Henry Grabowski, Follow-on Biologics: Data Exclusivity and the Balance Between
Innovation and Competition, 7 NATURE REviEws DRUG DIscovERY 479, 482 (2008).
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of drug failure in clinical trials.'0 Despite the high price tag on biologics,"
however, the risk may well be worth the reward.
Biologic drugs are typically either antibodies or recombinant versions of
proteins occurring naturally in the human body ("endogenous proteins"), and
the FDA defines them separately from "drugs." 2 Biologics are purposely
designed to share common physical features and properties with endogenous
molecules and, in consequence, should be expected to perform essentially
the same function in the body as endogenous molecules. If competing phar-
maceutical manufacturers independently develop biologic therapeutics
against a particular molecular target, it is quite likely that these distinct drugs
will share common features and properties. While biologics should closely
resemble endogenous molecules or parts thereof, however, they may also
have artificial structural features or elements.
Biologics differ from small-molecule drugs in several key aspects.
When compared with small-molecule drugs, biologics are quite large." Al-
though the structure of biologic drugs varies widely, the overall size differ-
ence between small-molecule drugs and biologics is likely to be several
orders of magnitude. Another essential difference between biologics and
small-molecule drugs is the means required to produce them. Like the pro-
teins they are designed to mimic, biologics are necessarily produced by cells,
typically either human or animal cells. Due to the high variability of cells, it
is impossible to ensure that their protein products are perfectly identical,
raising important manufacturing concerns.14
Thus, the question of what makes different types of drugs "similar" is
extraordinarily challenging, and the answer may be quite different for bio-
10. See, e.g., Joseph DiMasi & Henry Grabowski, Economics of New Oncology Drug
Development, 25 JOURNAL OF CLINICAL ONCOLOGY 209, 212 (2007), available at http://jco.
ascopubs.org/content/25/2/209.full.pdf+html (finding that approximately half of oncology
drugs in expensive Phase III clinical trials failed to gain FDA approval, and that one out of five
oncology drugs that entered the approval pipeline process between 1993 and 2002 actually
gained approval).
11. See Small Molecule, supra note 3. Biologics are far more expensive than small
molecule drugs and generics.
12. 42 U.S.C. § 262(i)(1) (2011) ("The term 'biological product' means a virus, thera-
peutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic prod-
uct, protein (except any chemically synthesized polypeptide), or analogous product . . .
applicable to the prevention, treatment, or cure of a disease or condition of human beings.").
The Centers for Biological Evaluation and Research ("CBER") and for Drug Evaluation and
Research ("CDER") of the FDA regulate a wide variety of biological products. See FDA 101:
Regulating Biological Products, U.S. FoOD & DRUG ADMIN., http://www.fda.gov/ForConsum
ers/ConsumerUpdates/ucm048341.htm#WhatbiologicalproductsdoesFDAregulate (last up-
dated July 25, 2008). For the purposes of this Note, my analysis concerns the types of drugs
regulated by CDER, which include monoclonal antibodies, cytokines, growth factors, en-
zymes, and immunomodulators.
13. See Small Molecule, supra note 3 (noting that a "typical monoclonal antibody" is
constructed of approximately 20,000 atoms).
14. See discussion infra Part II.A.
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logics and small-molecule drugs, as this Note will discuss. In contrast, the
approach to answering the question may be quite similar for both. One may
undertake an atom-by-atom comparison of two drugs in order to determine
whether they are structurally similar. Alternatively, one may compare the
physiological effect of two drugs by measuring their effect on a particular
cellular pathway or molecular target to determine whether they are function-
ally similar.
In order to tackle the complexity of biological similarity, it is first essen-
tial to set forth a realistic classification rubric for biologic drugs and pre-
cisely define the terms presently used to describe their constituents. For
reasons discussed above, it is impossible to create a true generic version of a
biologic. According to the FDA, a generic small-molecule drug is "chemi-
cally identical" and "bioequivalent" to a brand-name drug, terms that en-
compass a wide range of the drug's biochemical features." The closest and
most generic-like approximations of biologics are called "biosimilars" or
"follow-on biologics."' 6 As discussed further in Part II, "biosimilar" is a
regulatory term, subject to the FDA's finding that a new biologic is "highly
similar" to a preexisting "pioneer" or "reference" biologic already on the
market, in the generic manufacturer's hope that it will function as a generic
version thereof.'7 Like the makers of small-molecule generics, biosimilar
manufacturers can benefit from an accelerated FDA approval process, ex-
plained in Part II.A.3.
A third term generally used to describe drugs-perhaps applicable to
biologic drugs that are similar yet not perfectly identical-is "me-too" drugs
("MTDs"). Popular sources of MTD definitions conflict with each other"
and with the legal description.19 These inconsistent, "catch-all" definitions
15. See FDA Generic Drugs: Questions and Answers, U.S. Foon & DiRuG; A MIN.,
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm
(last updated Aug. 24, 2011) ("A generic drug is identical-or bioequivalent-to a brand name
drug in dosage form, safety, strength, route of administration, quality, performance characteris-
tics and intended use. . . . FDA requires generic drugs have the same high quality, strength,
purity and stability as brand-name drugs.").
16. See Liang, supra note 7, at 399. Although the U.S. originally adopted the term
"follow-on biologics," "biosimilar" is also now commonly used.
17. See, e.g., Market Opportunities for Biosimilars, GENERICS & BIOSIMILARS INIIA-
TivE (June 17, 2011), http://www.gabionline.net/Biosimilars/General/Market-opportunities-
for-biosimilars (anticipating $2 billion to be spent on biosimilar development by 2015, mainly
due to significant patent expiries of the pioneer biologics).
18. Compare, Me Too Drug, FRFE DICTlONARY, http://medical-dictionary.thefreedictio-
nary.com/me+too+drug (last visited Feb. 16, 2013) ("A popular term for a generic drug with
an identical formulation and stated indications as a previously FDA-approved agent."), with
Definition of Me-Too Drug, MEDICINENET, http://www.medterms.com/script/main/art.asp?
articlekey=33748 (last visited Feb. 16, 2013) ("A drug that is structurally very similar to al-
ready known drugs, with only minor differences.").
19. See USV Pharm. Corp. v. Richardson, 461 F.2d 223, 228 n.15 (4th Cir. 1972) ("A
'me-too' drug is generally defined as 'one which is equivalent to another, pioneer drug, which
preceded it on the market.'" (citing Note, Drug Efficacy and the 1962 Drug Amendments, 60
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may stem from a general difficulty with defining this group in a precise way.
The MTD label is commonly applied to small-molecule drugs, and it is un-
clear whether the term "biosimilar" will come to be interchangeable with
"me-too" in the context of biologics. Biosimilarity requires "high" similarity
defined by the FDA, while the MTD label implies a more indeterminate
level of equivalence. A fourth classification of biologic drugs termed "bio-
betters" 20 are therapeutics created when a manufacturer takes a reference
drug and alters its structure in a way that improves its function or perform-
ance in the body.21 Although brief, these descriptions of biosimilars, MTDs,
and bio-betters should indicate that the drugs in these groups have a high
degree of structural similarity to pioneers.
A fifth possible classification of biologic drugs includes biologics that
are functionally similar, but unlike the previous class of drugs, they may or
may not be structurally similar. These biologics have the same molecular
target or may act to affect the same cellular processes so that physicians can
use them to treat the same disease. In the interest of promoting as much
clarity as possible, this Note refers to drugs falling into this classification
scheme as "similar-impact biologics," although there may be conceptual
overlap with the MTD definition.
The groups listed above merely illustrate a possible way to classify
drugs based on the extent of their structural resemblance, underscoring that
defining biologic similarity is extraordinarily complicated. As this Note will
discuss, the answer varies among different institutions and agencies, as in
the course of the drug approval process or patent infringement litigation,
various agencies often must evaluate one drug's similarity to other drugs at
both a structural and functional level. In these evaluations, they may under-
take an atom-by-atom comparison of two biologics in order to determine
whether they are structurally similar. Alternatively, they may compare the
physiological effect of two biologics by measuring their effect on a particu-
lar cellular pathway or molecular target to determine whether they are func-
tionally similar.
These determinations can be a double-edged sword. As described below,
in the case of market approval by the FDA, similarity to a drug already on
the market can accelerate a generic therapeutic's approval, but such similar-
ity can also create problems for obtaining and retaining a patent, as decided
GEO. L. J. 185, 198 n. 78 (1971))), aff'd sub nom. USV Pharm. Corp. v. Weinberger, 412 U.S.
655 (1973).
20. See Biobetters Rather than Biosimilars, GENERICS & BIOSIMILARS INIATIVE (June
5, 2011), http://www.gabionline.net/Biosimilars/General/Biobetters-rather-than-biosimilars
("The enhancement [effect of bio-betters] may range from better efficacy, or a longer half-life,
allowing for a lower dosing frequency and reduced risk of immunogenicity, to lower toxicity
and reduced side effects.").
21. See, e.g., Biobetters Q&A, BIORESEARCH ONLINE (Sept. 7, 2011), http://www.biore
searchonline.com/doc.mvc/Biobetters-QA-0001.
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by the US Patent and Trademark Office ("USPTO"). Further, these agencies
are not the final word, and courts may get involved. Thus, biological similar-
ity from a legal perspective may be evaluated quite differently, depending on
the decision maker.
This Note explores how the regulatory and patent systems currently han-
dle complicated questions of biological similarity. Part I focuses on a family
of similar-impact biologic drugs as a case study to illustrate regulatory and
litigation challenges facing similar biologic and biosimilar development.
Part II describes the mechanics of biologic drug approval and discusses the
FDA's approach to similar drugs. Part III reviews selected areas of patent
law where biological similarity is of key importance and highlights instances
of disconnect between patent law and the FDA.
I. SIMILAR-IMPACT BIOLOGICS AND THEIR CHALLENGES: A CASE STUDY
OF THE TNFA INHIBITORS
A. Defining Drug Similarity
Perhaps the most prominent family of similar biologic therapeutic mole-
cules presently available on the market is the tumor necrosis factor alpha
("TNFA") inhibitors. These drugs interfere with the biological activity of
TNFA and act as immunosuppressants. To briefly summarize a complicated
signaling network, activated macrophages secrete TNFA into the body's ex-
tracellular milieu, where it recognizes and binds a variety of target receptors
("TNFRs") expressed on the surface of cells. TNFd's bioactivity is nuanced:
TNFd-TNFR binding activates molecular signaling pathways inside the cell,
which can ultimately turn on expression of genes that either mediate inflam-
mation or induce cellular death.2 2 Pathological dysregulation of TNF6 sig-
naling is implicated in diseases as diverse as rheumatoid arthritis, 2 3 chronic
plaque psoriasis, Crohn's disease (inflammatory bowel syndrome), and
cancer.
The three market-dominant TNFA inhibitors are Pfizer's Enbrel
(etanercept), Abbott Laboratories' Humira (adalimumab), and Remicade (in-
fliximab), produced by Centocor (a Johnson & Johnson subsidiary) and
Schering-Plough, among other assignees. These drugs exert their effects
through conceptually similar mechanisms. Enbrel is a soluble fusion protein
22. See, e.g., Lucia Cabal-Hierro & Pedro S. Lazo, Signal Transduction By Tumor Ne-
crosis Factor Receptors, 24 CEuL SIGNALING 1297 (2012); Thomas Helgans & Klaus Pfeffer,
The Intriguing Biology of the Tumour Necrosis Factor/Tumour Necrosis Factor Receptor Su-
perfamily: Players, Rules and the Games, 115 IMMUNOLOGY 1, 2 (2005) ("[I]t became appar-
ent that most members of the TNF superfamily interact with more than one receptor ....
[Later] it was possible to define the physiological function linked to individual ligands or
receptors in more detail and it became clear that almost each receptor-ligand system of this
TNF/TNFR superfamily appears to have a unique and non-redundant function.").
23. Bharat B. Aggarwal et al., Historical Perspectives on Tumor Necrosis Factor and
Its Superfamily: 25 Years Later, a Golden Journey, 119 Bi oon 651, 660 (2012).
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based on the TNF receptor. In the body, it acts as a competitive inhibitor of
TNF6-TNFR signaling via binding TNF6 and preventing it from interacting
with its target receptor. By comparison, Humira and Remicade are human-
and mouse-derived monoclonal antibodies, 24 respectively, that bind to the
TNFd molecule to block TNFR interaction. Thus, although Remicade and
Humira structurally resemble each other, but not Enbrel, all three molecules
act in a similar fashion. Importantly for the industry, these biologics are each
huge moneymakers-one analysis placed all three in the top four best-sell-
ing drugs of 201225-generating over $6 billion in sales that year.2 6 Unsur-
prisingly, competition for market dominance is fierce. 27
These three drugs each interfere with the same target, and recent data
indicate a statistically similar mortality rate when administered to patients. 28
Their biological activity is not identical, however. This finding is illustrated
in clinical studies of the TNFA inhibitors' effect on rheumatoid arthritis
("RA"), an autoimmune disease characterized by joint pain and degenera-
tion, and upon which most TNF6 inhibitor research has focused. The find-
ings of these studies can be broken down into two major points: drug
efficacy and relative safety.
The first point for comparison is drug efficacy: that is, how much is
required to have the desired therapeutic effect. In a four-year study of RA
patients taking one of the three drugs, patients stayed on Enbrel significantly
longer than on either Humira or Remicade.29 Perhaps not coincidentally, a
comparative effectiveness study found that RA patients taking Enbrel were
less likely to escalate their dose than patients on Humira and Remicade,10 as
dose escalation implies that patients have become nonresponsive to the drug
at lower doses. Similarly, Swiss researchers observed that patients developed
24. That is, antibodies that only recognize one site (or "epitope") on a particular protein.
25. John D. Carroll, The 15 Best-Selling Drugs of 2012, FIERc;PHARMA (Oct. 9, 2012),
http://www.fiercepharma.com/special-reports/15-best-selling-drugs-2012.
26. Rodney J.Y. Ho & Jenny Y. Chien, Drug Delivery Trends in Clinical Trials and
Translational Medicine: Growth in Biologic Molecule Development and Impact on Rheuma-
toid Arthritis, Crohn's Disease, and Colitis, 101 J. PHARMACEUlfAL Sc. 2668 (2012), availa-
ble at http://www.ncbi.nlm.nih.gov/pubmed/22573521.
27. Abbott/lEisai's Humira has Emerged as Leading Psoriasis Agent, PHARMALETTER
(Aug. 7, 2012), http://www.thepharmaletter.com/file/ 15519/abbotteisais-humira-has-
emerged-as-leading-psoriasis-agent.html.
28. See Julia F. Simard et al., Mortality Rates in Patients with Rheumatoid Arthritis
Treated with Tumor Necrosis Factor Inhibitors: Drug-Specific Comparisons in the Swedish
Biologics Register, 64 ARTHRITIS & RHEUMATISM 3502 (2012).
29. Florenzo lannone et al., Longterm Retention of Tumor Necrosis Factor-a Inhibitor
Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA
Registry: An Appraisal of Predictors, 39 J. RHEUMATOLOGY 1179, 1179 ("The mean duration
of therapy was significantly longer for etanercept (3.1 ± 2 yrs) than for adalimumab (2.6 ± 2
yrs) or infliximab (2.7 ± 2 yrs; p < 0.05).").
30. Vernon F. Schabert et al., Disability Outcomes and Dose Escalation with
Etanercept, Adalimumab, and Infliximab in Rheumatoid Arthritis Patients: A US-Based Retro-
spective Comparative Effectiveness Study, 28 CURRENr MED. Ros. & OPINION 569 (2012).
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resistance to Remicade more quickly than to Humira or Enbrel.3 ' They also
noted a reduction in therapeutic response after the first six months of Remi-
cade therapy, a finding that was not observed with the other two drugs.3 2 A
Danish study found that Remicade had the lowest rate of disease remission
and drug adherence, whereas treatment with Humira led to the best clinical
outcome." When solely compared with Enbrel, however, Remicade appears
to be more effective at preventing joint damage in RA patients. 34
Other comparative analyses of the TNFd inhibitors have focused on
their relative safety.3 5 In the Danish study, Enbrel recipients demonstrated
the longest survival rates, 36 and a subsequent meta-analysis of the literature
on TNFA inhibitors suggested that Enbrel might be the safest alternative.37
Specifically, the authors of that study noted that RA patients on Humira and
Remicade were more likely to discontinue the use of the drug due to an
adverse effect' than were patients on Enbrel.39 One French study found an
elevated risk of lymphoma in RA patients using the monoclonal antibody
therapeutics when compared to either Enbrel users or the population as a
whole,40 and Humira and Remicade have been associated with increased risk
of other diseases as well.4 ' These studies provide a sufficient picture of rela-
31. See A. Finckh et al., Evidence for Differential Acquired Drug Resistance to Anti-
Tumour Necrosis Factor Agents in Rheumatoid Arthritis, 65 ANNALS OI, RHIEUMATr ic DisHASES
746, 746 (2006) (finding significantly elevated requirements for co-therapy and dose escala-
tion for Remicade only, and no significant treatment discontinuation between drugs).
32. Id.
33. See Merete Lund Hetland et al., Direct Comparison of Treatment Responses, Remis-
sion Rates, and Drug Adherence in Patients with Rheumatoid Arthritis Treated with
Adalimumab, Etanercept or Infliximab: Results from Eight Years of Surveillance of Clinical
Practice in the Nationwide Danbio Registry, 62 ARTHRITIS & RHEUMATISM 22 (2010).
34. See Axel Finckh et al., The Effectiveness of Anti-Tumor Necrosis Factor Therapy in
Preventing Progressive Radiographic Joint Damage in Rheumatoid Arthritis: A Population-
Based Study, 54 ARTHRITIs & Ri-iuMArism 54 (2006) (finding a statistically significant differ-
ence [p = 0.02] when comparing disease progression in patients treated with antirheumatic
drug therapy plus either Enbrel or Remicade).
35. See Daniel E. Furst et al., Open-Label, Pilot Protocol of Patients with Rheumatoid
Arthritis Who Switch to Infliximab After an Incomplete Response to Etanercept: The Opposite
Study, 66 ANNAi-s RHEUMATIC DISEAsE. 893 (2007), reviewed by Axel Finckh, Comparative
Effectiveness of Rheumatoid Arthritis Therapies, 12 CURRENT RHEUMATOID REaroRls 348
(2010).
36. Hetland et al., supra note 33, at 28 fig. 3.
37. Kalle J. Aaltonen et al., Systematic Review and Meta-Analysis of the Efficacy and
Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis, PLoS ONE, Jan.
2012, at 1.
38. See What Is a Serious Adverse Event, Foon & DRUG ADMIN. (June 23, 2011), http://
www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm.
39. Aaltonen et al., supra note 37, at 7 tbl. 3.
40. X. Mariette et al., Lymphoma in Patients Treated with Anti-TNF: Results of the 3-
Year Prospective French RATIO Registry, 69 ANNALs RHEUMATIC DisnAsi: 400 (2010).
41. See Finckh et al., supra note 34, at 351 (discussing an increased risk of tuberculosis
and herpes zoster with use of the monoclonal antibody therapeutics).
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tive clinical efficacy and safety to enable an observer to distinguish between
these drugs, despite their similarity.
The big-picture cohort studies described above provide essential data for
decision making on the part of patients, doctors, regulatory agencies, and the
pharmaceutical industry, but they are not the only source of pertinent infor-
mation. Single-patient case studies also improve our understanding of the
kind of nuanced biological response that is likely to differentiate similar
drugs. One case study of an RA patient reported differences in liver re-
sponses to sequential treatment of Enbrel, Humira, and Remicade. 42 The pa-
tient's serum aminotransferase levels were elevated when treated with the
first two drugs, but normalized when switched to Remicade. 43 The authors of
the study remarked upon the complexity of liver injury that could result even
from treatment by different drugs in the same class of therapeutics.4
The takeaway message is that even biologic molecules with similar
structure and function-and those with a demonstrated strong safety profile,
like the TNFax inhibitors-may have noticeably disparate physiological im-
pact, particularly when the analysis becomes more fine grained. Further,
these complications are by no means limited to the TNFd inhibitors. Many
individual proteins serve diverse and numerous functions in the cell, a phe-
nomenon termed "moonlighting," 45 and the expression of endogenous pro-
teins is tightly regulated to modulate their biological effects.4 6 Thus, using a
biologic drug may have unexpected consequences either arising from the
drug's interference with cellular targets beyond the one intended for the ther-
apy, or from downstream effects of drug-target interaction. Proteins are also
frequently altered following cellular expression, commonly either as a result
42. Jose Carlos Titos-Arcos et al., Letter to the Editor, Recurrent Hepatotoxicity Associ-
ated with Etanercept and Adalimumab but Not Infliximab in a Patient with Rheumatoid Arthri-
tis, 104 Riv. Esi'. ENIERM. DiG. 282 (2012), available at http://www.grupoaran.com/mrm
Update/lecturaPDFfromXML.asp?IdArt=4620244&TO=RVN&Eng=l.
43. Id. at 282.
44. Id. at 283.
45. E.g., Constance J. Jeffery, Moonlighting Proteins, 24 TRENos BIOCHEMICAL ScI. 8
(1999). The consequence is that a biologic drug would also impact the same diversity of func-
tions as the molecule it is designed to resemble.
46. See, e.g., S. Thomas Carmichael, Gene Expression Changes After Focal Stroke,
Traumatic Brain and Spinal Cord Injuries, 16 CURRENr OPINIONs NEUROBItOoGY 699 (2003)
(describing wave-like patterns of gene expression following ischemic brain injury); Samantha
N. Greer et al., The Updated Biology of Hypoxia-Inducible Factor, 31 EMBO J. 2448 (2012),
available at http://www.nature.com/emboj/joumal/v3IIn I l/full/emboj2012125a.html (review-
ing the role of the HIFI transcription factor, which is selectively upregulated in hypoxic envi-
ronments, and which promotes expression of a plethora of pro-angiogenic genes).
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of post-translational modifications or proteolysis. 7 An unrelated area of con-
cern is biologics' ability to trigger an unwanted immune system response.4 1
Thus, even though they resemble endogenous molecules, these general
characteristics of biologics raise red flags about their safety. Scholars have
noted that this multi-factorial regulation of protein function has significant
implications for biosimilar manufacture, 49 as it may be difficult for manufac-
turers to control this element of production. 0 The situation becomes still
more complicated when the biosimilars enter into the picture, because they
are necessarily different from the pioneer molecule,' yet are designed to be
"highly similar" to it. Because manufacturers are already working to develop
biosimilar versions of some of the TNFA inhibitors, the FDA is certain to
face the question of whether these forthcoming drugs merit this label. 52
B. TNFd Inhibitor Litigation
The biological similarity between the two monoclonal antibody TNFA
inhibitors has led to infringement litigation between their two manufacturers.
In 2009, Remicade patent assignee Centocor sued Abbott Laboratories,53 as-
serting that the Humira patent 54 infringed several of its claims. 5
47. Examples of modifications include: glycosylation, phosphorylation, farnesylation,
prenylation, myristolyation, and ubiquitination. Proteolysis refers to the cleavage of a substrate
protein by an enzyme. This mechanism often yields bioactive fragments from a larger parent
molecule.
48. Robert N. Sahr, The Biologics Price Competition and Innovation Act: Innovation
Must Come Before Price Competition, B.C. INTiELL. PRoP. & TECH. F., July 19, 2009, at 12
("The propensity to become immunogenic is a special concern for large biologics that is gener-
ally not problematic for small molecule drugs.").
49. E.g., Liang, supra note 7, at 371; Sahr, supra note 48, at II ("In living cells, the
activity of chaperones or other molecules that interact with proteins during synthesis can add
variability to the end product.").
50. Trevor Woodage, Blinded By (A Lck of) Science: Limitations in Determining Ther-
apeutic Equivalence of Follow-on Biologics and Barriers to Their Approval and Commerciali-
zation, 2012 STAN. TECH. L. Rj-v. 9, $ 13 (describing the "multi-factorial nature of the
manufacturing substrates and methods" used in producing biosimilars); see also infra Part
IllI.A.3.
51. See infra Part Ill.A (discussing manufacturing problems of the biologics); Liang,
supra note 7, at 371 ("Because of the differences in production and size between biologics and
chemical drugs, as well as the unique cellular source of biologics, it is nearly impossible to
make truly identical copies of a protein using two different production cell lines."). According
to Liang and his sources, this impossibility precludes generation of a true generic biologic
molecule.
52. See infra Part II.A.3 for a discussion of the TNFd biosimilars.
53. Centocor Ortho Biotech, Inc. v. Abbott Labs., 669 F. Supp. 2d 756, 760 (E.D. Tex.
2009) ("[T]he Court finds that Abbott has not proven by clear and convincing [sic] that
[Centocor's] patent is unenforceable or invalid."), rev'd, 636 F.3d 1341 (Fed. Cir. 2011).
54. U.S. Patent No. 8,197,813 col. 51 1. 2 (filed Mar. 10, 2009) (claiming "[a]n isolated
human antibody, or an antigen-binding portion thereof, that dissociates from human TNF6
(hTNFi) with a Kd of lx10 8 M or less and a K,, rate constant of lxl0s or less").
55. U.S. Patent No. 7,070,775 (filed July 18, 2002).
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Although structurally similar, Remicade and Humira are distinctly dif-
ferent molecules. Their differences stem from the dissimilar initial creative
approaches of their respective manufacturers. 56 The portion of the Remicade
antibody that recognizes TNFd is technically a mouse protein, derived from
a mouse exposed to human TNF6. The other portion of the Remicade an-
tibody is a piece of human antibody. This fusion of proteins from different
species, termed a "chimera," prevents an unwanted immune response when
Remicade is injected into the human body.57 By contrast, Abbott's Humira is
an entirely human antibody, built piecemeal from an existing library of
human-derived molecules previously screened for capability to bind TNFA.
In pursuing litigation against Abbott, Centocor argued that Humira's
properties infringed the Remicade patent, despite the structural differences
described above. At trial, the jury agreed with Centocor and awarded a $1.67
billion verdict, one of the largest in patent infringement litigation history. 9
Given the structural similarity between the two molecules, this outcome may
not have been totally surprising. The Federal Circuit subsequently reversed
the trial verdict, however, holding that Centocor's claims to a fully human
antibody exceeded the scope of its original written description. 60 This saga
and its sequence of outcomes highlights two issues: it serves as a discrete
example of the kinds of biological differences that juries and judges must
confront in these cases, and it suggests potential problems with the ability of
juries to handle highly technical material, discussed further in Part HI.B.61
While the TNFd inhibitors are only one family of similar-impact bio-
logics, their challenges are informative and potentially representative of
what other manufacturers of similar-impact biologics will confront. The
same issues are likely to appear for other families of biologics where the
molecules have identical targets but very different structural components.
56. Centocor, 636 F.3d at 1344, 1346 ("in developing their therapeutic TNF-6 antibo-
dies, Centocor and Abbott pursued very different strategies. Centocor's path began by identify-
ing a mouse antibody to human TNF-A that had both high affinity and neutralizing
activity . . . . Abbott decided to work with collaborators to construct a fully-human antibody
from scratch."), cert. denied, 132 S. Ct. 1542 (2012).
57. See id. at 1344-45.
58. See id. at 1346.
59. E.g., Bruce Japsen, Abbott Wins Appeal in $1.67B Humira Patent Infringement
Case, CHI. TRIm. (Feb. 26, 2011), http://articles.chicagotribune.com/2011-02-23/business/
ct-biz-0224-abbott-humira-201102241_humira-rheumatoid-arthritis-drug-knoll-pharmaceuti
cals-abbott-laboratories.
60. Centocor, 636 F.3d at 1353. See infra Part Ill.A for an explanation of these terms'
significance.
61. Also see infra Part Ill.D for a discussion of decision making.
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II. INTERPRETING BIOLOGICAL SIMILARITY: FDA AS DECISION MAKER
A. The FDA and Biological Similarity
Over the past half century, the FDA's duty has been to determine that
drugs are safe and effective for market. 62 With few exceptions, 63 the FDA is
not required nor encouraged to assess the comparative effectiveness of the
drugs it approves.1"4 Despite this fact, the FDA still considers questions of
drug equivalence, most significantly in the context of determining whether
generic drugs may enter the market. Much of the FDA's interpretive prece-
dent is limited to small-molecule drugs, and the advent of the biosimilars
will force the agency to answer the new question of what makes two bio-
logics "highly similar."
1. Equivalence Assessments of Small-Molecule Drugs
How should the FDA handle biologics equivalence? Several statutory
and regulatory definitions are possible and will be discussed in this Note.
Most definitions derive from the FDA's treatment of small-molecule drugs,
and it is unclear how much this reasoning will, or should, carry over into
evaluating biological similarity.
First, it is important to note that biologics are different from small-mole-
cule drugs. As described in the Introduction, Congress initially drew a dis-
tinction between the FDCA's drug and the Public Health Service Act's
("PHSA") "biological drug," giving each term its special meaning.
The FDA has further elaborated on these definitions, creating analytical
frameworks for their assessments. In implementing the Orphan Drug Act,
the FDA tackled the question of what makes two drugs "the same" drug.6 1
Significantly, the FDA clearly distinguished between small-molecule drugs6 6
62. See, e.g., The Food and Drug Administration's Critical Mission and Challenges for
the Future Before the H. Comm. on Oversight and Gov't Reform, 110th Cong. 39-49 (2007)
(statement of Andrew C. Von Eschenbach, Comm'r, Food & Drug Admin.).
63. In determining whether two drugs are the "same" under the Orphan Drug Act, see
21 C.F.R. § 316.3(b)(13) (2012) ("[Ihf the subsequent drug can be shown to be clinically supe-
rior, it will not be considered to be the same drug.").
64. See Robert J. Temple, Comparative Effectiveness Research, Foon & DRUG AuMIN.
2 (Apr. 21, 2010), http://www.fda.gov/downloads/Drugs/NewsEvents/UCM209270.pdf
("FDA's experience with comparative effectiveness claims is relatively limited. Our enabling
law . . . does not require assessment of comparative effectiveness and the legislative history
made it very clear there was no relative effectiveness requirement."). Perhaps unintentionally,
this duty is expanding with the advent of the recently enacted biosimilar approval pathway,
described supra Part II.A.2.
65. See generally 21 C.F.R. § 316 (2012).
66. 21 C.F.R. § 316.3(13)(i) (2012) ("[A] drug composed of small molecules, a drug
that contains the same active moiety as a previously approved drug and is intended for the
same use . . . except that if the subsequent drug can be shown to be clinically superior to the
first drug, it will not be considered to be the same drug.").
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and larger drugs ("macromolecules"), 67 a category which encompasses and
delineates between protein drugs, polysaccharide drugs, polynucleotide
drugs, and "[c]losely related, complex partly definable drugs with similar
therapeutic intent."16
The FDA has created a thorough framework to compare the generic ver-
sions of small-molecule drugs with their pioneer counterparts. In making
these determinations, the agency considers a variety of distinctions69 :
namely, the drugs' therapeutic equivalence, pharmaceutical equivalence, and
bioequivalence. To be therapeutically equivalent, the two small-molecule
drugs must be pharmaceutically equivalent and bioequivalent. 70 According
to the FDA's Orange Book,7' pharmaceutical equivalence means that two
drugs have the same active ingredients, are of the same dosage form, use the
same route of administration, and are identical in strength or concentration. 72
Bioequivalence means the "equivalent release of the same drug substance
from two or more drug formulations."" Therapeutic equivalence means that
two drugs are pharmaceutical equivalents that can be expected to have the
same clinical effect and safety profile when prescribed according to speci-
fied conditions, and do not present any bioequivalence problems.7 4
Presently, there is no Orange Book equivalent for biologics. For reasons
described below, perhaps there should be, because biologics and their ge-
neric biosimilars pose unique challenges in evaluating similiarity.
2. Separate Procedural Consequences for Small-Molecule Drugs
and Biologics
Differences in defining drugs can lead to different procedural conse-
quences, such as the means by which these drugs are approved for com-
merce.75 In the case of small-molecule drugs, manufacturers must apply for a
67. Id. § 316.3(13)(ii) ("[A] drug composed of large molecules (macromolecules), a
drug that contains the same principal molecular structural features (but not necessarily all of
the same structural features) and is intended for the same use as a previously approved drug,
except that, if the subsequent drug can be shown to be clinically superior, it will not be consid-
ered to be the same drug." (emphasis added)).
68. Id. § 316.3(13)(ii)(A)-(D).
69. See, e.g., Solvay Pharm., Inc. v. Ethex Corp., No. Civ. 03-2836 JRTFLN, 2004 WL
742033 (D. Minn. Mar. 30, 2004).
70. Id. at *2 ("[These generic applications require] the manufacturer of the similar drug
to demonstrate that the two drugs are therapeutically equivalent, that is pharmaceutically
equivalent and bioequivalent." (footnotes omitted)).
71. Foon & DRUG AoMN., ArPRovED DRUG PRODUCTS WITH THERAPEuric EQUIVA-
EiNCE EVALUATIONS (2012), available at http://www.fda.gov/ucm/groups/fdagov-public/
@fdagov-drugs-gen/documents/document/ucm071436.pdf [hereinafter ORANGE BOOK].
72. Id. at vi-vii; see also 21 C.F.R. § 320.1(c) (2012).
73. 21 C.F.R. § 320.1(f) (2012); id. § 355(j)(8)(B); ORANGE BOOK, supra note 71, at
viii.
74. ORANGE BOOK, supra note 71, at vii.
75. See generally 21 U.S.C. § 355 (2011).
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New Drug Application ("NDA") to bring their new product to market.76
Under the Drug Price Competition and Patent Term Act (commonly referred
to as the Hatch-Waxman Act), generic small-molecule drug manufacturers
may take advantage of an accelerated approval pathway called an Abbrevi-
ated New Drug Application ("ANDA"), which references a previously ap-
proved drug. In order to make use of the accelerated pathway, the
application must contain information showing that the active ingredients in
the generic drug are the same77 as those of the pioneer, that they share the
same route of administration, dosage form, and strength,7 and that the two
drugs are bioequivalent. 79 This pathway allows generic sponsors to bring
their product to market without the same kind of clinical showing required
for the pioneer drug by relying on the latter's clinical data, thereby accelerat-
ing the availability of lower-cost generics to patients.
In contrast to these procedures for small-molecule drugs, there are sev-
eral avenues presently available for moving biologic drugs through the
FDA's regulatory process. 0 As a brief overview, the primary route for ob-
taining approval for biologic drugs is for manufacturers to pursue a new
Biologic License Application ("BLA"), as set forth in the PHSA. A small
number of biologic drugs can make use of the FDCA section 505(b)(2), the
original pathway for small-molecule drug approval. For biosimilars, this lat-
ter approval pathway is only available to biosimilars referencing a limited
number of biologics approved through new drug applications ("NDAs")."'
As for generic small-molecule drugs, the FDA may approve biosimilars
via a different route than the one for their respective pioneer biologic drugs.
The BPCIA, enacted as part of the Patient Affordable Care Act on March 23,
2010, creates a shortcut for biosimilar approval. It amends the PHSA sec-
tion 351(k) to create an "abbreviated licensure pathway" for biological prod-
ucts shown to be biosimilar to a reference product already licensed by the
FDA. Use of a pioneer's clinical drug data to facilitate approval and gain the
"biosimilar" label is intended to expedite the presence of these biosimilar
drugs on the market.8 2
According to the revised standards of section 351(k), a proposed biolog-
ical product with demonstrated biosimilarity (i.e., a "biosimilar" product)
can come to market by relying on certain existing scientific knowledge per-
taining to the reference product. 3 The statute provides that biosimilars may
76. Id. § 355(j).
77. Id. § 355()(2)(A)(ii)(1-ll).
78. Id. § 355(j)(2)(A)(iii).
79. Id. § 355(j)(2)(A)(iv).
80. Liang, supra note 7, at 384-92.
81. See Noel Courage & Ainslie Parsons, The Comparability Conundrum: Biosimilars
in the United States, Europe and Canada, 66 Foon & DRu; L.J. 203, 213 (2011).
82. This approach is similar to that created for generic small-molecule drugs in the
Hatch-Waxman Act. See 21 U.S.C. § 355(j).
83. 42 U.S.C. § 262(k)(2)(A)(i)(I-V) (2011).
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also be found "interchangeable" with a pioneer product, if the biological
product is both biosimilar to and "expected to produce no meaningful
clinical difference" from the reference product.8 4 As others have noted, this
distinction means that "interchangeable" is a higher bar than "biosimilar." 5
3. A New Challenge: Defining the Highly Similar Biologic
Early in 2012, the FDA published a Draft Guidance describing how a
biosimilar manufacturer might craft an application to navigate this abbrevi-
ated approval pathway.16 According to the Draft Guidance, the FDA must
find that a biosimilar is "highly similar" to the reference product, with "no
clinically meaningful differences" between the biosimilar and the reference
drug in terms of "safety, purity, and potency."8 7 To meet these requirements,
a biosimilar must satisfy a sophisticated totality-of-the-evidence standard,
including comparisons of the biosimilar and the reference drug with respect
to structure, function, animal toxicity, pharmacochemical attributes such as
pharmacokinetics and pharmacodynamics, clinical immunogenicity, and
clinical safety and effectiveness." The same concerns must be satisfied for
"interchangeable" biologics, with the additional requirement of clinical simi-
larity. This latter requirement is phrased so as to be open ended, however, as
the amount of clinical data required will depend on "the extent of residual
uncertainty about the biosimilarity of the two products." 9
Ultimately, the FDA has the final decision on adequacy of scientific
justification. 9() Consequentially, the FDA has the discretion to determine that
any particular element-for example, the studies on biological similarity,
effects on animals, and clinical studies of safety, purity, or potency-is un-
necessary in a section 351(k) application.9' Further, "clinically meaningful"
merely requires a difference in the expected range of safety, potency, and
purity, not a slight difference in the rates of occurrence of adverse events
when comparing two biological products. 92 At present, it is unclear how the
FDA will interpret "highly similar" in the context of biosimilar applications.
84. Id. § 262(k)(4).
85. Jonathan Stroud, The Illusion of Interchangeability: The Benefits and Dangers of
Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process, 63 ADMIN. L. REV.
599, 626 (2011).
86. Foon & DRUG ADMIN., GUIDANCE FOR INDUSTRY: SCIENTIFIC CONSIDERATIONS IN
DEMONSTRATING BIOSIMILARITY TO A REFERENCE PRODUCT (2012), available at http://www.
fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM
291128.pdf [hereinafter DRAFr GUIDANCE].
87. Id. at 3.
88. Id. at 7.
89. Id. at 12.
90. See generally id. at 5 (giving the FDA discretion to require less data from studies).
91. Id.
92. Id. at 8 (emphasis added).
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Manufacturing concerns pose a special problem in creating this defini-
tion. Other scholars have discussed the difficulty of producing therapeuti-
cally equivalent biosimilars,93 and one described the situation as follows:
"Because of the differences in production and size between biologics and
chemical drugs, as well as the unique cellular source of biologics, it is nearly
impossible to make truly identical copies of a protein using two different
production cell lines."94 This impossibility, he argues, ultimately precludes
generation of a true generic biologic molecule. The subsequent therapeutic
implications are likely to be profound, and others have noted that "[i]t is a
particular challenge with biosimilars to know which variations matter clini-
cally and which will have no impact."9' The FDA has also identified some
additional problematic properties of biosimilars that cannot be quantified but
nonetheless impact their function: specifically, post-translational modifica-
tions, three-dimensional folding, and aggregation,'9 6 which may be affected
by manufacturing processes. The FDA offers guidance on quality controls,97
and this will be presumably be useful for biosimilar development.
In sum, manufacturers face at least two foreseeable challenges with re-
spect to the approval process: FDA development of its biosimilar approval
mechanism and difficulties of manufacturing. These complications have not
hindered generic pharmaceutical companies from anticipating the FDA's in-
terpretation and planning their biosimilar development accordingly.98 For
example, representatives of Sandoz Biopharmaceuticals-a leading generics
manufacturer-describe "goal posts," which define the desirable
pharmacochemical attributes for a particular biosimilar.99 These goal posts
represent the range of characteristics of the "originator" pioneer molecule
that occur through manufacturing change; i.e., due to scaling up the manu-
facturing process or transferring the manufacture to other facilities. If the
93. Specifically, sources have addressed biochemical and pharmacological similarities:
structure / composition, pharmacokinetics, and efficacy in animals, as discussed in the DRAF
GUIDANCE, supra note 86; see, e.g., Woodage, supra note 50, at 23 ("A possible avenue for
gaining experience with the abbreviated-approval process is . . . start[ing] with 'baby steps,'
initially considering less complex biologics, such as those molecules that can be produced in
bacterial cells and have a lower risk of immunogenicity because they do not undergo post-
translational glycosylation.").
94. Liang, supra note 7, at 371.
95. Courage & Parsons, supra note 81, at 204.
96. Berkowitz et al., supra note 8, at 527.
97. Foon & DRUG ADMIN., GUIDANCE FOR INDUSTRY QI I DEVELOPMENT AND MANU-
FACTURE oi DRUG SUBSTANCEs, 16 (2012), available at http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatorylnformation/Guidances/UCM261078.pdf ("Data derived from
commercial-scale batches should confirm results obtained from small-scale studies used to
generate data in support of process validation. . . . The limit of in vitro cell age for commercial
production should be assessed.").
98. Mark McCamish & Gillian Woollett, Worldwide Experience with Biosimilar Devel-
opment, 3 MAus 209 (2011).
99. Id. at 214. The authors illustrate the concept nicely in Figure 4.
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biosimilar's activity falls within the pioneer's benchmarks, the biosimilar
manufacturer should feel confident that the FDA will accept their product.'"
Absent firmer guidance from the FDA regarding how to make a "highly
similar" drug, this initial approach seems reasonable.
Although the FDA has not yet approved any biosimilars for the U.S.
market, the TNFd inhibitors serve as a useful example of things to come, as
biosimilar versions of Enbrel have already been developed and characterized
in South Korea.o'0 Recent research upon the effects of these biosimilars has
already illustrated some of the key concerns. Despite similar
pharmacokinetic profiles, one study noted that more subjects receiving the
biosimilar drug for treatment reported adverse side effects than did subjects
who received Enbrel.102 In a subsequent comparative study of two Enbrel
biosimilars, the authors identified multiple-but arguably minor-differ-
ences in the structure of one biosimilar as compared to that of Enbrel. 03
After performing a battery of functional assays, however, the researchers
ultimately concluded that there was little observable functional difference
between the two products, despite the lack of perfect structural similarity.'0
It is arguable whether these types of scientific findings, absent further
clinical showing, would be sufficient to constitute the high similarity re-
quired to approve a biosimilar through the accelerated pathway. Approval
would certainly seem to require the FDA to squint at the structural data. The
FDA is not interested in perfect similarity between two biologic molecules,
according to the Draft Guidance; rather, the FDA will focus upon the lack of
meaningful clinical differences between Enbrel and any biosimilar attempt-
ing to replicate its therapeutic effects.
Thus, if the biosimilar's manufacturers were to pursue its approval for
the U.S. market, the kinds of differences observed above may not torpedo its
100. Id. at 212 ("If the [biosimilar] product attributes fall within the variability of the
originator molecule after manufacturing change, then the biosimilar should be considered
'highly similar.'").
101. Namyi Gu et al., Comparative Pharmacokinetics and Tolerability of Branded
Etanercept (25 mg) and Its Biosimilar (25 mg): A Randomized, Open-Label, Single-Dose,
Two-Sequence, Crossover Study in Healthy Korean Male Volunteers, 33 CLINICAL THERAPEU-
ics 2029 (2011); Qingqiao Tan et al., Characterization and Comparison of Two Commer-
cially Available TNF Receptor 2-Fc Fusion Protein Products, 4 MAus 761 (2012); SoJeong
Yi et al., Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed
Etanercept (Enbrel@): A Double-Blind, Single-Dose, Crossover Study in Healthy Volunteers,
26 BioDRUGS 177 (2012) (finding similar pharmacokinetic profiles when tested in healthy
adults).
102. Gu, supra note 101. Eleven out of twenty-one subjects receiving biosimilar therapy
reported adverse effects, whereas eight of twenty-one Enbrel-treated subjects did.
103. Tan, supra note 101 (recognizing a protein sequence difference of only two amino
acids, relatively low sialylation of N-oligosaccharides, and differences in charge attributes be-
tween the two drugs).
104. Id. at 761 ("Interestingly, [the biosimilar] exhibited similar affinity and bioactivity
levels compared with [Enbrel] despite the obvious difference in primary structure and partial
physiochemical properties.").
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approval through the accelerated pathway, particularly if the drug's safety
profile is strong. On the other hand, doctors and their patients would benefit
from a greater understanding of the biosimilar's ability to reduce or elimi-
nate the symptoms of disease, such as joint degeneration or pain in RA pa-
tients, but these potential clinical outcomes cannot be properly extrapolated
from these comparisons as performed.
B. Making the Decisions: A Role for Experts
As described above, the FDA's competency is evaluating drug safety
and efficacy on the basis of data submitted in a premarket application. Ap-
proving biosimilars requires the FDA to answer a new question: whether a
new biologic drug is similar enough to its pioneer that the latter's data can
apply to the former, absent an actual showing to this effect. It is important to
emphasize here the distinction that generic small-molecule drugs are "the
same as" their pioneers, whereas biosimilars are "highly similar" to theirs.
Accordingly, the question is qualitatively different, and the factors impli-
cated in a "highly similar" analysis invite a more nuanced approach. The
difficulties in biosimilar manufacture further complicate the picture, as dis-
cussed previously. Finally, the FDA's own Draft Guidance leaves much
flexibility in terms of what data is sufficient to draw the "highly similar" or
"interchangeable" comparisons. Overall, these complications render the bi-
osimilar approval process significantly different from the approach to the
generic small-molecule drug approval. Because these questions are new and
different, the "highly similar" analysis raises significant institutional compe-
tency concerns.
It is possible that the FDA will be able to acquire the competency to
address these concerns as it gains familiarity with biosimilar applications, in
the same manner that it considers applications for generic versions of small-
molecule drugs.'0 An alternate means of alleviating some of these concerns
is for the FDA to seek outside expert help in interpreting the premarket simi-
larity of these drugs by convening one of its thirty-three advisory commit-
tees.'o6 The FDA regularly involves experts in the consideration of new drug
applications. Following receipt and review of an application for a new drug
or biologic, the FDA determines whether outstanding questions need to be
addressed."" If so, the FDA then convenes advisory committee meetings for
the purpose of soliciting expert input.'o Observers have noted that the
105. See supra note 76 and accompanying text.
106. See Advisory Committees, Foon & DRUG ADMIN., http://www.fda.gov/Advisory
Committees/CommitteesMeetingMaterials/default.htm (last updated Dec. 16, 2011).
107. Jeffrey F. Smith et al., FDA Advisory Meeting Outcomes, II NATURE Ruviuws
DRUc, DiScovERY 513, 513 (2012).
108. Id.
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FDA's decision to approve a new drug often closely tracks the advice pro-
vided by the experts at these advisory meetings. 09
The FDA exercises its discretion in deciding whether to convene an ad-
visory committee. 0 Generally, the FDA may choose to do so when the mat-
ter is of significant public interest, controversial, or would benefit from a
special type of expertise."' In the context of biosimilar drug approval, there
will necessarily be an outstanding question of whether the drug is highly
similar to its reference. Logically, the FDA should reach out to experts with
strong expertise in structural and functional biology in order to reach the
best answer. The FDA will likely be amenable to this suggestion, as they
already sought input from stakeholders on multiple areas relevant to biosimi-
lar development in the process of developing the Draft Guidance,1 2 and they
are thought to have a rather conservative approach to the approval of new
drugs in general."'
Use of experts is no panacea. "Experts" are not fungible, and the FDA's
selection criteria for committee membership are fairly open ended: members
should be technically qualified experts in their field and have experience
interpreting complex scientific data."l 4 Further, despite the selection of inde-
pendent experts, the FDA allows representatives from the pharmaceutical
industry to attend advisory committee meetings. Some authors have argued
that the industry's influence makes the FDA susceptible to agency cap-
109. Id. at 514 ("The FDA approved 88% of the original NDAs or BLAs that were en-
dorsed by its advisory committees, and did not approve 86% of those that the committees did
not endorse.").
110. Fool & DRUG ADMIN., GUIDANCE FOR THE PunuIC AND FDA STAFF ON CONVENING
ADvIsoRY COMM-IfEE METINGS: DRAFI GUIDANCE (2008), available at http://www.fda.gov/
downloads/Regulatorylnformation/Guidances/UCM 12565 1.pdf.
111. Id. at 4.
112. Id. As reflected in the Draft Guidance, these include: (1) factors that the FDA
should consider in evaluating "highly similar;" (2) factors that the FDA should consider in
determining what analytical, animal, or clinical studies should be used to assess the potential
impact of structural differences; (3) the range of structural differences consistent with "highly
similar;" (4) circumstances where the FDA should find that additional animal or clinical stud-
ies are unnecessary.
113. See Nicholas S. Downing et al., Regulatory Review of Novel Therapeutics-Com-
parison of Three Regulatory Agencies, 366 NEw ENG. J. MED. 2284, 2288 (2012). At least, so
argue these authors, based on a finding that the FDA only approved 61.8% of new drugs after
one cycle of review, which classified it as conservative compared with other international drug
approval agencies.
114. In selecting experts for committee participation, a key concern is whether there is a
conflict of interest. See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR THE PUBUc, FDA ADvI_
SORY COMMITFEE MEMBERS, AND FDA STAFF ON PROCEDURES FOR DETERMINING CONFLICT
OF INTEREST AND EIGIBILITY FOR PARTICIPATION IN FDA ADVISORY COMMrffEFs (2008),
available at http://www.fda.gov/downloads/Regulatorylnformation/Guidances/UCM125646.
pdf. Otherwise, membership requirements are minimal, at least as stated by the FDA; Advisory
Committees: Membership Types, FOOD & DRUG ADMIN., http://www.fda.vgov/AdvisoryCom
mittees/AboutAdvisoryCommittees/CommitteeMembership/MembershipTypes/default.htm
(last updated July 15, 2010).
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ture.I" Other safeguards are needed to alleviate these concerns, and one pos-
sibility is increased monitoring of postmarket safety data for biosimilars.
C. Making the Decisions: A Role for Postmarket Safety Data
Approving any drug is a health and safety gamble, even when extensive
preclinical testing occurs. Although much previous scholarship has focused
upon challenges in biosimilar approval, an equally concerning issue is how
best to make certain that the approval, once earned, was in fact merited.
If a drug is shown to be unsafe, there are procedures in place to identify
and remove approved drugs from the market. Once a drug is on the market,
CDER handles reports related to drug safety, and individuals have the op-
portunity to submit accounts of drug-related health incidents. But it is the
manufacturers and not the FDA that have the burden of following up on
safety concerns for a particular drug." 6 Although the FDA can require drug
manufacturers to submit reports of adverse events or manufacturing
problems," 7 this system is rife with administrability problems, as others
have amply documented."'
Generally, if a drug poses health risks, comparative effectiveness data
could suggest alternatives to its use. Since the FDA does not track this infor-
mation, however, it may never be gathered." 9 If these data are to be col-
lected, a reasonable argument can be made that this burden should not fall
upon the drug manufacturers. The perception of a conflict of interest may be
too difficult to eliminate, even in well-conducted studies. For example, re-
cent work suggests that physicians are less likely to view research funded by
a pharmaceutical company as conducted with a high level of rigor and may
be consequently more reluctant to prescribe these drugs.'12( Even if pharma's
115. See, e.g., Amalea Smirniotopoulos, Bad Medicine: Prescription Drugs, Preemption,
and the Potential for a No-Fault Fix, 35 N.Y.U. Rav. L. & Soc. CHANG 793, 808-12 (2011)
(defining agency capture as "[mianufacturers' influence over regulators and malfeasance").
116. 21 U.S.C. § 355(k)(3) (2011).
117. See Postmarketing Surveillance Programs, Foon & DRUG ADMIN., http://www.fda.
gov/Drugs/GuidanceComplianceRegulatorylnformation/Surveillance/ucm090385.htm (last up-
dated Aug. 19, 2009).
I 18. See, e.g., Matthew Gordon, Improving Post-Approval Risk Surveillance for Drugs:
Active Post-Market Risk Identification, 15 MICH. TEL.COMM. & TECH. L. REv. 297 (2008),
available at http://www.mttlr.org/volfifteen/gordon.pdf; Smirniotopoulos, supra note 115, at
809 ("[P]atients with serious or terminal illnesses and their families have long criticized the
FDA for failing to approve new drug therapies fast enough, or for revoking approval after a
drug proves to be unsafe for some patients.").
119. E.g., Furst et al., supra note 35, at 348 ("Once a drug is approved for a particular
indication, manufacturers have no incentive to conduct expensive head-to-head trials to deter-
mine the relative benefit of the new treatment against the current best treatment.").
120. Aaron S. Kesselheim et al., A Randomized Study of How Physicians Interpret Re-
search Funding Disclosures, 376 NEw ENG. J. MED. 1119 (2012).
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studies reveal important results, the effect of this perception may obfuscate
the true value of the findings.121
The present systems indicate significant problems with collecting these
data. However, they should be collected if consumers are to be protected
adequately. Although bioequivalence for a drug is determined prior to its
market availability, much safety-related information only becomes available
after the drug reaches consumers, and clinical trial information only serves
as a proxy for subsequent treatment protocols.12 2 Because these data more
accurately indicate the performance of the drug in the relevant population,
consideration of this postmarket safety data (also termed pharmacovigilance)
should be at least as important to analyses of drug safety as is premarket
safety data.
In particular, postmarket safety data can be used to distinguish among
similar drugs. To anticipate how the FDA will handle future assessments of
drug similarity, the FDA's treatment of a family of similar selective small-
molecule inhibitors of cyclooxygenase-2 (COX2) may be informative. These
drugs, Celebrex (celecoxib), Bextra (valdecoxib), and Vioxx (rofecoxib),
were originally approved to treat pain via inhibition of COX2 activity,123 and
although these three drugs do not have perfectly identical structures, they do
share similar functions. They thus may be considered MTDs.124 The FDA
subsequently revoked Vioxx's approval following significant elevated rates
of heart attacks in patients, to great publicity, and Bextra's manufacturer
later voluntarily pulled it from the market.125 Only Celebrex remains on the
U.S. market,126 despite an increased incidence of similar cardiovascular
events as shown for the other two drugs.127
This story highlights certain clear benefits of postmarket safety data, as
they reveal the details of a drug's real world performance. Further, this ex-
ample illustrates the special challenge facing the FDA if safety problems
121. Id. at 1125 ("Pharmaceutical companies seeking to enhance the appropriate use of
important new products or to expand the appropriate uses of existing products must address the
attitudes that our survey revealed, so that the credibility of the results of industry-supported
trials is more likely to be based on methodologic rigor than on funding sources.").
122. See, e.g., lannone et al., supra note 29, at 1179 ("Our study provides further evi-
dence that the real-life treatment of patients with RA may be different from that of randomized
clinical trials.").
123. See COX-2 Selective (Includes Bextra, Celebrex, and Vioxx) and Non-Selective
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Foon & DRUG ADMIN., http://www.fda.
gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucml03420.
htm (last updated Nov. 27, 2012) [hereinafter NSAIDs].
124. Sid M. Wolfe, WORST Pli s, BEST Pu js: A CONSUMER'S GUIDE TO PREVENTING
DRUG- INi)UcEI) DEATH 303 (2005) ("Valdecoxib is another redundant "me-too" drug in the
crowded NSAID family of drugs. This drug is chemically similar to celecoxib .
125. NSAIDs, supra note 123.
126. Id. In contrast, all three drugs were pulled from Canada's market.
127. Scott D. Solomon et al., Cardiovascular Risk Associated with Celecoxib in a
Clinical Trial for Colorectal Adenoma Prevention, 352 NEw ENG. J. MED. 1071 (2005).
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emerge for drugs with a high degree of structural resemblance. It will not
always be evident whether the adverse events stem from the parts of the
drugs that make them structurally similar, so that all should be pulled from
the market, or from those that are different between the members of the drug
family, which would justify keeping others available for patients' use.
Problems will arise no matter which response the FDA makes. One possibil-
ity is to pull all members of the drug family from the market, but this may be
an overreaction, particularly when some patients depend greatly upon them.
The alternative is for the FDA to consider each drug separately, requiring a
great deal of time and expense. But, as the COX2 inhibitor example shows,
mere structural and functional similarity of drugs does not guarantee that the
FDA will respond to their identified risks in the same manner.
Postmarket safety data also confers other, more politic, advantages over
premarket safety data. Even if the FDA chooses to compel the industry to
conduct clinical trials, it must still rely heavily upon the industry's own rep-
resentations of fact in order to bring drugs to market. A stronger focus on
postmarket safety data obviates these concerns and provides a deeper and
more accurate picture of the drug's performance in the entire population than
even premarket Phase III clinical trials can provide. Of interest, recent evi-
dence suggests possible misrepresentation of Celebrex's safety data in per-
suading the FDA to allow Pfizer to keep it on the market.128 Whether or not
this allegation is ultimately borne out, this saga serves as a cautionary tale,
highlighting the weakness of the FDA as an independent evaluator of drug
safety.
While the COX2 inhibitors are small-molecule drugs and not biologics,
their story underscores some important concerns that the FDA will face in
handling the approval of biologic drugs that are not only similar, but highly
similar. As patents for many pioneer drugs are expected to expire soon, the
importance of carefully tracking safety data for approved biosimilars will
become increasingly apparent. Though the FDA's present concern is how
much premarket safety data should be required for biosimilar approval, it
should also invest heavily in closely tracking the postmarket performance of
these drugs.
III. INTERPRETING BIOLOGICAL SIMILARITY: PATENT LAW
AS DECISION MAKER
Like the FDA, the patent legal system must also routinely interpret bio-
logical similarity. This system, generally comprising the USPTO and the
Federal Circuit, answers statutory questions of biologic drug patentability or
128. See Katie Thomas, In Documents on Pain Drug, Signs of Doubt and Deception,
N.Y. TIMEs (June 24, 2012), http://www.nytimes.com/2012/06/25/health/in-documents-on-
pain-drug-celebrex-signs-of-doubt-and-deception.htmlpagewanted=all&_r-0 ("[The FDA]
swallowed [Pfizer's] story, hook, line, and sinker.").
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of infringement. In patent law, biochemistry and pharmacology are part of
the so-called unpredictable arts,12 9 as small alterations in small-molecule and
biologic drugs can affect efficacy and function in surprising ways. 3' Never-
theless, it is equally clear that not all small changes merit a patent.
The context of interpretation is different from that of the FDA: the pat-
ent legal system only decides whether the drug merits patent protection and
ignores questions of safety and efficacy. But because both institutions evalu-
ate biological similarity, it is worth exploring differences in their definitions
and the extent to which the patent legal system adopts the FDA's
terminology.
A. Hurdles to Biologic Patentability
Patentability is evaluated in the course of a biologic's application to the
USPTO or in the course of a patent infringement suit. Obtaining patent pro-
tection requires a drug to clear a variety of patentability hurdles. The essence
of the patent system is to reward inventions that are new, useful, and nonob-
vious1'3 by affording the patent holder a significant property right: the ability
to exclude others from making, using, and selling the invention.132 The in-
vention itself is defined by a combination of the patent application's written
description,133 which must be enabling,134 as well as the claims, 35 which
precisely define the bounds of the invention. Although the subject matter of
pharmaceutical drugs is necessarily complex, the Federal Circuit has stated
that there is no particular "super-enablement" standard for biological or
chemical patents.'3 6
129. See, e.g., In re Fisher, 427 F.2d 833, 839 (C.C.P.A. 1970) ("In cases involving
unpredictable factors, such as most chemical reactions and physiological activity, the scope of
enablement obviously varies inversely with the degree of unpredictability of the factors
involved.").
130. The converse is also true: even though a disease may have obvious targets against
which to develop a therapeutic, drugs typically have a very high failure rate in both preclinical
and clinical trials.
131. See 35 U.S.C. §§ 101-103 (2011).
132. Id. § 154(a)(1) (2011).
133. See id. § 112; see also Sheila R. Arriola, Biotechnology Patents After Festo: Re-
thinking the Heightened Enablement and Written Description Requirements, II FED. CIR. B.J.
919, 936 (2002) ("For unpredictable arts [the written description] 'requires a precise definition,
such as by structure, formula, chemical name, or physical properties.'" (citing Fiers v. Revel,
984 F.2d 1164, 1171 (Fed. Cir. 1993))).
134. See Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010). The
written description must be sufficient to enable a person having ordinary skill in the art to
make and use the invention without undue experimentation.
135. Arriola, supra note 133, at 919 ("The claims of a patent are prescribed by statute for
the purpose of making the patentee define precisely the scope of the invention.").
136. See Ariad, 598 F.3d at 1352 ("The [written description requirement] never created a
heightened requirement to provide a nucleotide-by-nucleotide recitation of the entire genus of
claimed genetic material; it has always expressly permitted the disclosure of structural features
common to the members of the genus.").
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Further, a new biologic drug must be neither anticipated by'"3 nor obvi-
ous in light of'" the prior art in order for its inventor to obtain a patent
thereon. These separate analyses have different foci and accordingly differ-
ent implications for biologic drug patentability. Novelty is evaluated through
a point-by-point comparison with another product or prior art reference.139
By contrast, obviousness analyses depend upon the state of knowledge in the
pharmaceutical and biomedical research fields at the time of drug develop-
ment and the motivations to create particular therapeutics.14 0
Patent infringement occurs when one group's product infringes a senior
party's patent property right by making, using, selling, or importing the
drug. The court may consider two questions, depending on which defenses
the accused infringer asserts: (1) the manufacturer's patent validity,141 and if
declared valid, (2) whether the alleged infringer's product infringes, either
literally or under the doctrine of equivalents.142
Beyond expensive patent infringement litigation costs, resolving these
cases is likely to lead to significant administrative costs on future courts,
which must evaluate extremely technical material in order to solve legal
questions. Although many aspects of patentability are reviewed de novo on
appeal and issues such as claim construction in one case may be non-
precedential in another,143 judges may still follow or rely on reasoning in a
137. 35 U.S.C. § 102 (2011), amended by Patent Law Treaties Implementation Act of
2012, Pub. L. No. 112-211, 126 Stat. 1527 (effective Dec. 18, 2013). Lack of novelty can only
be established by a single prior art reference that discloses each and every element of the
claimed invention, a fairly strict identity requirement for all elements of the claimed invention.
138. Id. § 103; Michelle L. Evans, Establishing Obviousness of Biotechnology Patent
Under 35 U.S.C.A. .§ 103, 122 AM. JuR. 313 PRoOF OF FACIS § I (2011) ("With chemical
structures and sequence listings used in biotechnological patents, obviousness typically de-
pends on the structural similarities and differences between the products claimed and the prior
art. If a scientist of ordinary skill in the appropriate art would have been motivated to select
and then modify a prior art compound to arrive at the compound claimed in the patent at issue
with a reasonable expectation that the new compound would have similar or improved proper-
ties to the prior art compound, then obviousness is established." (footnotes omitted)).
139. See, e.g., Perricone v. Medicis Pharm. Corp., 432 F.3d 1368, 1378 (Fed. Cir. 2005)
("[W]hen considering a prior art method, the anticipation doctrine examines the natural and
inherent results in that method without regard to the full recognition of those benefits or char-
acteristics within the art field at the time of the prior art disclosure.").
140. See Graham v. John Deere Co., 383 U.S. 1, 17 (1965) (requiring comparison of the
claimed invention with the pertinent prior art, from the perspective of an objective person
having ordinary skill in the art); KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (finding
that the PTO's exclusive use of the "teaching, suggestion, or motivation" test to determine
obviousness is impermissible). Although rigid application of the TSM test is precluded by
KSR, the doctrine is still frequently used in analyzing obviousness.
141. That is, whether the patent was improperly granted.
142. See Graver Tank v. Linde Mfg. Co., 339 U.S. 605, 607-09 (1950); see also infra
Part IlI.C.
143. Al-Site Corp. v. VSI Int'l, Inc., 174 F.3d 1308, 1322 (Fed. Cir. 1999) (finding reli-
ance on prior Federal Circuit case only allowed for issue preclusion and not precedential for
the claim construction itself). Other lower courts may not feel the same way as the Federal
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case that has similar legal issues but different scientific issues. These con-
ceptual difficulties have the potential to create inconsistent or problematic
precedent, if reasoning is improperly extrapolated between cases. Thus,
careful attention must be paid to what similarity actually entails. Part III.B
below discusses the reasoning in some recent cases pertaining to aspects of
biological similarity, paying particular attention to the legal concepts of ob-
viousness and equivalence.
B. Defining Biologic Obviousness
Obviousness is a statutory barrier to a drug's patentability.'" While
small-molecule drugs have long been subjected to analyses of obviousness,
it is not clear that courts should extend the rationale in these earlier cases to
questions of obviousness for biologic patentability, for reasons discussed
below.
The common law test for obviousness has changed noticeably over time
and can incorporate several levels of analysis. Earlier courts routinely ap-
plied the factors of the Graham test, which required an evaluation of the
scope and content of the prior art, the relative skill of persons having ordi-
nary skill in the pertinent art ("PHOSITAs"), and a subsequent point-by-
point comparison between the new invention and the prior art to determine
whether the invention was obvious.'14 Presently, the USPTO also considers
whether there is a "teaching, suggestion, or motivation" to develop a drug
that may render it obvious, but this test is not mandatory,146 and the USPTO
must take an expansive and flexible approach to evaluating obviousness.'14
The discussion must begin, as before, by distinguishing between small-
molecule drugs and biologics. Small-molecule drugs are synthesized com-
pounds with no natural role in biological function. Thus, it is extraordinarily
difficult to look at a small-molecule drug and accurately predict its effects in
the human body. Consequentially, new small-molecule drugs may easily
dodge the obviousness bar. This ability seems less certain for biologics. Bio-
logics, like small-molecule drugs, are fundamentally clusters of atoms. But
unlike small-molecule drugs, they mimic molecules with highly specific,
tightly regulated functions that have evolved over millennia.
Further, as discussed in the Introduction, "biologics" is itself a compli-
cated term and these drugs pose concerns that small-molecule drugs avoid.
Circuit, however. See, e.g., Permacel Kansas City, Inc. v. Soundwich, Inc., No. 03-0766-CV-
W-HFS, 2006 WL 1449979, at *3 (W.D. Mo. May 24, 2006) ("It would, however, be reckless,
to say the least, for me to rule in a manner inconsistent with an unpublished opinion of a panel
of the reviewing court.").
144. 36 U.S.C. § 103 (2011).
145. Graham, 383 U.S. at 17 (creating a four-factor test for obviousness).
146. See KSR, 550 U.S. at 399.
147. Id. at 415 (referencing the Court's long use of an "expansive and flexible" approach
when considering questions of obviousness).
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For example, biosimilars and bio-betters are designed to be structurally simi-
lar or highly similar to the reference, but may be functionally different due
to manufacturing issues. Similar-impact biologics, which may have some-
what or very different structures, may be designed to have a similar function,
as in the case of the TNFi inhibitors.
Rebecca Eisenberg has noted that courts have treated obviousness in-
quiries inconsistently, with alternating focus on the drugs' structure or on
their function,148 but suggests that were the Supreme Court to come down on
one side or another, the Court would prefer the latter's more flexible ap-
proach.149 But there is a logical disconnect in measuring the "obviousness"
of an "unpredictable" compound before much is known about its function
and effect.
The structural comparison part of the traditional obviousness analysis is
straightforward and thus relatively unobjectionable. Obviousness of a drug is
technically measured from the time of its invention (but from the filing date
for patents filed after March 16, 2013).5) This timing may be appropriate for
analyses that compare drugs' atomic structures with those of prior art drugs,
where differences in the drugs' blueprints are clear, discrete, and reliably
identifiable. This point-by-point comparison of structural features provides a
foundation by which a patent examiner can state whether the drug is obvious
in light of the prior art.
The functional comparison part of this analysis is trickier, and warrants
consideration of a long-established tradition of case law evaluating obvi-
ousness of the function of small-molecule drugs. In determining whether
these drugs are obvious, courts will often evaluate so-called "secondary con-
siderations" of obviousness, which include a showing of unexpectedly better
results for a drug than would have been predicted by an objective PHOSITA
of drug development. For example, courts have found that a new drug may
not be obvious if the manufacturer can show that his product has greater
utility than would normally be expected.'
Even so, superior properties of a subsequent small-molecule drug may
not always be sufficient to render it nonobvious.152 Courts are willing to
draw lines, but it is unclear where these lines should be drawn. For example,
148. See Rebecca S. Eisenberg, Pharma's Nonobvious Problem, 12 Lewis & CLARK L.
REV. 375, 407 (2008).
149. Id.
150. Leahy-Smith America Invents Act, Pub. L. No. 112-29, § 3(c), 125 Stat. 284
(2011).
151. In re Soni, 54 F.3d 746, 751 (Fed. Cir. 1995) ("Given a presumption of similar
properties for similar compositions, substantially improved properties are ipso facto unex-
pected."); In re Blondel, 499 F.2d 1311, 1315 (C.C.P.A. 1974) ("[Chemical compounds are
nevertheless unobvious and patentable if their proofs show . . . that the increase in duration of
activity is greater than those skilled in the art would have any reason to expect.").
152. See, e.g., Aventis Pharma Deutschland v. Lupin, Ltd., 499 F.3d 1293 (Fed. Cir.
2007) (finding obvious the superior performance of a drug composed of stereoisomers with
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courts have shown some disagreement over whether the results themselves
should be unexpected or whether the magnitude or degree of the results
should be unexpected. 53 Even observed synergy, a kind of unexpectedly
superior result, may not save a combination drug from invalidation for obvi-
ousness if the motivation to create the drug was obvious. 5 4 While the logic
of these cases is informative, they concern the properties of small-molecule
drugs. It is not clear how far their rationale will, or should, logically extend
to cases involving biologics.
Arguably, the obviousness analysis should be different when consider-
ing development of biologics than for small-molecule drug therapies. In the
course of drug development, manufacturers are guided by the desire to de-
velop effective therapies for a particular disease. A PHOSITA will assuredly
appreciate the logical incentives for developing a particular biologic drug;
indeed, failure to do so would lead to much wasted time and effort by the
developer. Often, the reasonable starting place is the underlying molecular
mechanism of a disease, such as the pathologically elevated levels of TNFd
that characterize RA. For example, if a PHOSITA wants to block TNFd
from binding a receptor, he can effectively trick TNFd into binding a decoy
target designed to mimic the receptor. Enbrel is a prime example of this type
of drug. In these cases, the target is obvious. The biochemical methods and
protocols are familiar and well characterized. The prior art is often the com-
ponents of the body itself, shaped by millennia of human evolution. Impor-
tantly, there is a reasonable expectation that the drug will work for the
intended purpose.' 55 But this raises the question of whether all biologic
drugs should be considered inherently obvious, and therefore unpatentable,
simply because there are strong incentives to pursue them.
heightened bioactivity, when the improved bioactivity was expected due to an increase in the
amount of the effective stereoisomer).
153. See In re Merck, 800 F.2d 1091, 1099 (Fed. Cir. 1986) ("Regarding the anticholin-
ergic effect, ... both drugs have anticholinergic effects but to a different degree. These are not
truly unexpected results. . . . The core of it is that, while there are some differences in degree
between the properties of amitriptyline and imipramine, the compounds expectedly have the
same type of biological activity.").
154. See Richardson-Vicks Inc. v. Upjohn Co., 122 F.3d 1476, 1483 (Fed. Cir. 1997)
("Evidence of secondary considerations, including evidence of unexpected results and com-
mercial success, are but a part of the 'totality of the evidence' that is used to reach the ultimate
conclusion of obviousness."). In Richardson-Vicks, another small-molecule drug case, the Fed-
eral Circuit affirmed a finding of obviousness even when "synergy" was observed in a novel
drug combination, following the district court's rejection of an examiner's finding of nonobvi-
ousness due to unexpectedly superior analgesic properties (merely additive effects would have
protected 50% of subjects, but the drug protected 80%). The district court reasoned that the
motivation to combine the two pain medications would have been obvious.
155. See In re Kubin, 561 F.3d 1351, 1360 (Fed. Cir. 2009).
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Presently, biologic drugs with the same target, similar structure, and vir-
tually identical function can obtain patents.'5 6 Methods of creating biologic
drugs may not be invalid for obviousness even if virtually identical drugs are
created via the same mechanisms. 5 In some cases, abuse of the "unpredict-
able" label may render the obviousness analysis absurd.
In Amgen, the Federal Circuit considered two essentially indistinguish-
able means of producing biologically active erythropoietin ("EPO"),'ss an
important regulator of blood production in the body which may be manufac-
tured as a biologic drug. The Federal Circuit interpreted Roche's patent
claims as follows:
The cells described [in Roche's patent] are "capable of glycosylat-
ing" EPO and are transfected with DNA encoding a polypeptide
"having an amino acid sequence sufficiently duplicative of that of
erythropoietin to allow possession" of the stated biological activi-
ties. Neither of these limitations . . . however, requires that the cells
actually produce isolatable amounts of glycosylated EPO having the
stated in vivo bioactivity. 59
The court distinguished these claims from those in Amgen's patents,
noting that "[i]n contrast, the asserted claims of [Amgen's patents] do re-
quire actual production of isolatable amounts of the in vivo biologically ac-
tive EPO glycoprotein."' 60 The court subsequently determined that Amgen's
claims were not invalid for obviousness, focusing upon what it saw as the
"main difference" between the two patents: "the actual production of isolat-
able glycosylated EPO having the stated in vivo biological activities."' 6 ' No-
tably, the court's holding does not dwell on any rationale that Roche's
scientists might have had for originally selecting the cells that it chose to
produce the EPO. Rather, the court dealt with the observation that Roche's
cells do, in fact, produce the desired glycosylated (biologically active) EPO
by reasoning that "having the stated biological activity is one of hindsight,
not of reasonable expectation of success at the time of the invention."1 62
156. As described in the discussion of TNFi inhibitor litigation, supra Part II.B, both
antibodies were able to obtain patents.
157. See, e.g., Amgen Inc. v. F. Hoffman-La Roche Ltd., 580 F.3d 1340 (Fed. Cir. 2009).
158. Id. at 1361 ("[Roche's patent] recites a CHO cell-a mammalian cell capable of
glycosylating EPO-transfected with a DNA sequence encoding a polypeptide having an
amino acid sequence sufficiently duplicative of that of EPO to allow possession of the stated
biological properties. Claims [in Amgen's patents] recite processes of producing EPO that
involve (a) growing mammalian cells transfected with DNA encoding EPO and (b) isolating
from those cells glycosylated EPO having the stated biological properties.").
159. Id. at 1361.
160. Id.
161. Id. (emphasis added).
162. Id. at 1363.
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Even considering the unpredictability of the biochemical arts, this dis-
tinction may seem strange. Surely a PHOSITA, having set up a system spe-
cially designed to produce a biologic drug, would expect it to work for this
purpose, even if actual production of biologics is a difficult and problematic
endeavor. The reasoning in this case suggests that the obviousness hurdle
can be an extraordinarily low bar to patentability, and much may depend on
the claim drafter's skill.
At the most extreme end, some scholars have argued that the nonobvi-
ousness requirement should be eliminated altogether, as it generally creates
perverse incentives in drug development, particularly because the drugs
most likely to be effective would be especially vulnerable to this means of
invalidation.16 3 Given that the requirement does not seem to be much of a
bar, perhaps it would not be missed too much. On the other hand, one possi-
ble argument for retaining the obviousness analysis in biologics cases is that
it might be useful for some manufacturers to demonstrate unexpectedly su-
perior properties in a given drug's structure. This argument resurrects some
of the logic in small-molecule drug obviousness analyses, but perhaps there
is still a place for this rationale.
The nonobviousness requirement raises a higher bar for biosimilars. The
very nature of a highly similar product, for which similarity is an essential
element of its design, seems to forbid its patentability altogether. As dis-
cussed previously, biosimilars are necessarily different from their reference
drugs in ways that do not apply to generic small-molecule drugs due to their
simpler means of manufacture, and the TNFa biosimilars in Part I show that
structural and functional differences are entirely plausible. Accordingly, it is
possible to conceive of biosimilars that could merit their own patent. Fur-
ther, discussions of biosimilar patents do not preclude the issue,'" although
patent protection for biosimilars might be an undesirable strategy for other
reasons.165 Of course, introduction of unpatented biosimilars following ex-
piry of the reference drug patent will avoid the problems of infringement and
obviousness altogether.
163. Benjamin N. Roin, Unpatentable Drugs and the Standards of Patentability, 87 TErx.
L. REv. 503, 536 (2009) ("It denies patent protection to the drugs that appear most likely to
succeed at the time they are invented and that have expected beneficial properties, i.e., the
drugs that appear most promising in early research."). Roin goes on to say: "The courts and
PTO apply this test without hesitation, finding drugs to be unpatentable whenever their thera-
peutic properties are considered unsurprising." Id. However, his claim appears largely to re-
volve around alterations to typical small-molecule drugs.
164. See Yaniv Heled, Parents vs. Statutory Exclusivities in Biological Pharmaceuti-
cals-Do We Really Need Both?, 18 MICH. TELECOMM. & TECH. L. REV. 419 (2012), availa-
ble at http://www.mttlr.org/voleighteen/heled.pdf; D. Alan White, Comment, The Doctrine of
Equivalents: Fairness and Uncertainty in an Era of Biologic Pharmaceuticals, 60 EMORY L.J.
751, 762 (2011).
165. See generally Heled, supra note 164. Heled essentially argues that the statutory
exclusivity period created by the BPCIA for biosimilar drugs precludes the need to obtain a
patent therefor.
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C. Defining Biologic Equivalence
The doctrine of equivalents is a weapon in a patentee's arsenal to ex-
clude competition by an extremely similar product. The thrust of the doc-
trine of equivalents is that a product or process that does not literally infringe
upon the express terms of a patent claim "may nonetheless be found to in-
fringe if there is 'equivalence' between the elements of the accused product
or process and the claimed elements of the patented invention."'6 6 Thus, in
order to find infringement under the doctrine of equivalents, a court must
determine that the potentially infringing product infringes each element of
the patented product.'16  The two traditional tests of equivalence are (1) to
compare differences between products to determine if these changes are "in-
substantial," and (2) to determine if the accused product's element "performs
substantially the same function in substantially the same way to obtain the
same result" as the claim limitation,'68 an analysis known as the function-
means-result test. A determination of product equivalence is, intuitively, a
complicated task that requires significant factual inquiry'6 9 and is reviewed
under the clear error standard. 7"
A similarly flexible rationale is applied when determining equivalence
of competitive products.' 7 ' In the case of drugs, courts consider both a com-
166. Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 21 (1997) (citing
Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605 (1950)); see also Lupin Ltd. v.
Abbott Labs., 491 F. Supp. 2d 563, 568 (E.D. Va. 2007) (citing Zelinski v. Brunswick Corp.,
185 F.3d 1311, 1316 (Fed. Cir. 1999)), aff'd sub nom. Abbott Labs. v. Sandoz, Inc., 566 F.3d
1282 (Fed. Cir. 2009).
167. Paul N. Katz, The Doctrine of Equivalents and Its Impact on "Designing Around," 4
FED. CIR. B.J. 315, 324 (1994) ("To aid the federal district courts in determining what is
'substantially the same,' the Federal Circuit endorsed the 'All Elements' rule which states that
equivalents cannot exist per se unless a literal or equivalent counterpart exists in the accused
device for each and every recited claim element.").
168. Warner-Jenkinson, 520 U.S. at 38 (quoting Union Paper-Bag Mach. Co. v. Mur-
phy, 97 U.S. 120, 125 (1878)); see also id. at 19 ("In the Court's view, the particular linguistic
framework used to determine 'equivalence,' whether the so-called 'triple identity' test or the
'insubstantial differences' test, is less important than whether the test is probative of the essen-
tial inquiry: Does the accused product or process contain elements identical or equivalent to
each claimed element of the patented invention?").
169. Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605, 609 (1950) ("What
constitutes equivalency must be determined against the context of the patent, the prior art, and
the particular circumstances of the case.").
170. Abraxis Biosci., Inc. v. Mayne Pharma (USA) Inc., 467 F.3d 1370, 1379 (Fed. Cir.
2006) ("Unlike claim construction, a matter of law reviewed de novo, infringement under the
doctrine of equivalents is a factual determination that we review for clear error.").
171. Graver Tank, 339 U.S. at 609 ("Equivalence, in the patent law, is not the prisoner of
a formula and is not an absolute to be considered in a vacuum. It does not require complete
identity for every purpose and in every respect. In determining equivalents, things equal to the
same thing may not be equal to each other and, by the same token, things for most purposes
different may sometimes be equivalents.").
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pound's structure and its function, and these comparisons may be qualitative
or quantitative in nature.172
While biochemistry is often thought of as an unpredictable art for which
small changes can lead to significant and unexpected effects, some qualita-
tive effects of changes are foreseeable.173 This foreseeability applies to bio-
logics in a way that it may not for entirely artificial small-molecule drugs.
Proteins are composed of amino acids, which are discrete building blocks. In
evaluating the equivalence of any parts of the protein, the primary focus
must be on a protein's amino acid sequence-and not on any underlying
DNA nucleotide sequence-because amino acids, not nucleotides, contrib-
ute directly to biologic function. As building blocks, amino acids are not
fungible.174 Accordingly, a change from one neutral amino acid to another
may have no discernible effect on the protein's function, 75 but a change
from a neutral amino acid to a charged amino acid may have significant
functional consequences.'7 6 A final step is to consider the context of the
placement of the mutation in the molecule.' All these qualitative aspects of
protein composition can affect function and should factor into equivalence
assessments.
It may be conceptually easier for courts to evaluate quantitative con-
cerns in their equivalence inquiries, as suggested by the analyses of secon-
dary considerations of obviousness, in Part III.B. As a recent example, the
Teva Biopharmaceuticals district court considered whether a competitor
therapeutic differed substantially from a biologic multiple sclerosis drug,
172. In re Papesch, 315 F.2d 381, 391 (C.C.P.A. 1963) ("From the standpoint of patent
law, a compound and all of its properties are inseparable; they are one and the same thing. The
graphic formulae, the chemical nomenclature, the systems of classification and study such as
the concepts of homology, isomerism, etc., are mere symbols by which compounds can be
identified, classified, and compared.").
173. Graver Tank, 339 U.S. at 609 ("Consideration must be given to the purpose for
which an ingredient is used in a patent, the qualities it has when combined with the other
ingredients, and the function which it is intended to perform. An important factor is whether
persons reasonably skilled in the art would have known of the interchangeability of an ingredi-
ent not contained in the patent with one that was.").
174. Arriola, supra note 133, at 927 ("Each of the twenty amino acids has distinct chemi-
cal properties: acidic, basic, uncharged polar, and nonpolar.").
175. Id. ("A 'conservative substitution' refers to the swapping of amino acids within the
same chemical property category, for example, switching one nonpolar amino acid for another.
This type of modification, especially where it occurs away from a functional domain of the
protein, may have little or no effect on the resulting biological function." (footnotes omitted)).
176. Consider the wide variety of diseases that are linked to a single amino acid substitu-
tion as a result of a few nucleotides' difference: sickle cell disease, bipolar disorder, macular
degeneration, and some variants of Tay-Sachs disease. In these diseases, the pathology and
symptoms directly stem from the change to the protein itself, and only indirectly from changes
to the gene.
177. Some alterations may occur within a protein-binding or domain-mediating intermo-
lecular recognition, where a change is likely to hugely affect function, whereas some may fall
within a hydrophobic core or linker and have little effect.
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based upon the numerical ratio of its amino acid composition.", In alleging
infringement, the manufacturer showed that a deviation of up to 12% in the
6:2:5:1 ratio of four amino acids would not be expected to have a material
effect on the biological activity of the drug.' 9 Because the court found that
the alleged infringer's drug differed in composition from the former drug
only by 4.5%, the court determined that it would not be expected to have
materially different biological activity.8 0 When considering the functional
significance of individual amino acids with respect to their placement in the
protein, consideration of only numerical ratios may often be an insufficient
metric in determining equivalence, for reasons described above.
Some scholars have suggested, via empirical studies, that use of the doc-
trine of equivalents is in decline.'8 ' Yet it has been invoked in several recent
cases as a means of finding infringement between biologic drugs.'8 2 These
cases illustrate the difficulties facing the courts in balancing similarities of
these molecules with the unpredictability of the art itself. If the doctrine of
equivalents is in decline, the advent of biosimilars may serve as an opportu-
nity to resurrect it.'"
D. Expanding the Role of Regulatory Guidance
Answering questions of biologic similarity in the context of patent law
reveals an abundance of moving parts. The complexity of these concerns
raises significant questions about who should make decisions regarding bio-
logic similarity. The statutory criteria constitute either questions of law, such
178. Teva Pharm. USA, Inc. v. Sandoz, Inc., 876 F. Supp. 2d 295 (S.D.N.Y. 2012).
179. Id. at 345.
180. Id. ("Accordingly, the molar ratio of [the infringer's] proposed product is insubstan-
tially different from approximately '6:2:5: .'") (emphasis added).
181. See, e.g., John R. Allison & Mark A. Lemley, The (Unnoticed) Demise of the Doc-
trine of Equivalents, 59 STAN. L. Rev. 955 (2007); Lee Petherbridge, On the Decline of the
Doctrine of Equivalents, 31 CARDOzo L. Riv. 1371 (2010).
182. E.g., Abraxis Biosci., Inc. v. Mayne Pharma (USA) Inc., 467 F.3d 1370, 1382 (Fed.
Cir. 2006) ("[W]e conclude that the district court's conclusion that Mayne's generic propofol
formulation infringes the patents in suit under the doctrine of equivalents was not clearly
erroneous. The court correctly determined that [the infringer's antimicrobial additive] calcium
trisodium DTPA performs substantially the same function in substantially the same way to
achieve the same result as [the patentee's antimicrobial additive] edetate."); Boehringer v.
Schering-Plough, 320 F.3d 1339 (Fed. Cir. 2003) (finding of infringement even when evidence
showed that the two viruses differed by at least seventy-three nucleotides and that the accused
infringing virus exhibited substantial differences from the original); Teva, 876 F. Supp. 2d
295.
183. But see David L. Schwartz, Explaining the Demise of the Doctrine of Equivalents,
26 BIERKFLEY TECH. L.J. 1157, 1160 (2011) (reviewing Allison & Lemley, supra note 182, and
Petherbridge, supra note 182). The author suggests that changes in patent litigation due to
Markman v. Westview Instruments, 517 U.S. 370 (1996)-namely its holding that claim con-
struction is a question of law for judges-has changed the focus of patent litigation to claim
construction as a way to evaluate the reach of a claim. Schwartz concludes that, in conse-
quence, the doctrine of equivalents has become a less important means of achieving this goal.
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as enablement and obviousness, or questions of fact, such as the written
description requirement. Although questions of fact are traditionally the pur-
view of the jury, the questions often overlap, and a judge may make the
ultimate decision.'8 4 There has been a trend to give judges more of this
power, at least in some areas of patent law,' 5 and it is not without reason.' 6
However, it is not at all certain that shifting the burden of resolving
patent issues onto the shoulders of lay judges is the best solution for resolv-
ing questions of scientifically complex material.'" One proposal is that, if
regular juries are not up to the task, the court should empanel juries of ex-
perts'"8 or appoint a special master.'8 9 Another alternative could be to im-
prove the role of the jury, perhaps by requiring special types of jury
instructions in patent infringement cases. It is possible that the observed
problems with juries simply stem from problems understanding their legal
challenge, not their ability to comprehend the scientific material. If so, a
carefully crafted special verdict form could preserve the value of the jury's
analysis while still guiding and focusing its attention on resolving key find-
ings, limiting instruction "to the core factual issues that control the ultimate
verdict." 90
A final possibility is for patent law judges to embrace aspects of the
FDA's regulatory determinations in evaluating biological similarity, when
appropriate. As discussed above, biological similarity determinations are
significant in analyses of obviousness and equivalence. Yet the legal system
treats the FDA's findings inconsistently between these two legal conclu-
sions. Patent courts take a very different approach in incorporating the
FDA's regulatory determinations in analyzing obviousness than they do in
analyzing equivalence. Regulatory bioequivalence has been acknowledged
to play a role in some aspects of patentability, notably obviousness, where
the Federal Circuit has recently stated that it is "most certainly relevant" to
184. For example, determining whether a patentee's acts constitute experimental use is
technically a question of law, but it is a highly fact-intensive inquiry. The dissent in Lough
argued that the heavy factual basis should be a reason to defer to the jury's findings. Lough v.
Brunswick Corp., 86 F.3d 1113, 1123 (Fed. Cir. 1996) (Plager, J., dissenting).
185. E.g., Markman, 517 U.S. 370 (holding claim construction to be a question of law).
186. The litigation between Centocor Biotech and Abbott Labs discussed supra Part .B
illustrates the sorts of problems or confusion that can emerge when lay juries confront highly
technical or scientific material.
187. Besides promoting verdict uniformity, however, the benefits of allocating this task
to judges, who are typically scientifically untrained, are unclear. Outside the context of pat-
ents, others have remarked upon how consolidating this power in the hands of these individu-
als can have uniformly unpleasant, not to mention scientifically unsound, outcomes. See Lisa
Heinzerling, Doubting Daubert, 14 J.L & Po.'y 65 (2006) for a good review.
188. This is White's solution: see White, supra note 165.
189. FED. R. Civ. P. 55.
190. See Charles M. Cork, A Better Orientation for Jury Instructions, 54 MERCER L.
REv. 1 (2002).
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that analysis."' This is consistent with the low bar to patentability that obvi-
ousness poses.
In contrast, equivalence for the purposes of patent infringement litiga-
tion is distinct from regulatory bioequivalence,19 2 and patent courts have
been historically reluctant to let the latter be determinative in the former's
inquiry.'9 3 In determining whether two drugs are equivalent, the FDA is pri-
marily interested in comparisons of their respective therapeutic safety and
effectiveness.194 In contrast, the doctrine of equivalents requires an "ele-
ment-by-element" comparison of the claimed invention and the accused in-
fringing product with respect to the drugs' functions, means, and results. 93
Although regulatory bioequivalence may not dispose of this inquiry, it is not
entirely irrelevant.' 9 6 For example, its inclusion is likely to depend upon how
much of the biologic's therapeutic function is described in the patent claims.
Although some policy considerations underlying the separateness of
these analyses are understandable,'"9 the reasons for this continued separa-
tion are unclear, particularly in view of the biosimilar's "highly similar" re-
quirements. As described in Part II.A-B, the FDA and its advisors make
informed decisions about the similarity of drugs. They will soon be making
further decisions about whether biologic drugs may be sufficiently function-
ally similar that they may be considered "highly similar." These conclusions,
191. See, e.g., In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent
Litig., 676 F.3d 1063, 1083 (Fed. Cir. 2012) ("At its core, Mylan and Par's proof of obvi-
ousness is that the claimed [pharmacokinetic] profile is bioequivalent to the immediate-release
profile. In rejecting the sufficiency of Mylan and Par's proof, we do not hold that bioe-
quivalence can never serve as evidence of obviousness. Indeed, it is most certainly relevant to
that inquiry.").
192. See Reckitt Benckiser Inc. v. Watson Labs., Inc., 430 F. App'x 871, 878 (Fed. Cir.
2011) ("[The Federal Circuit] clarified, however, that 'bioequivalency and equivalent infringe-
ment are different inquiries.'" (citing Abbott Labs. v. Sandoz, Inc., 566 F.3d 1282, 1298 (Fed.
Cir. 2009))); Johns Hopkins Univ. v. Datascope Corp., 543 F.3d 1342, 1348 n.3 (Fed. Cir.
2008) ("[T]he jury may have concluded that the regulatory submission was evidence of
equivalency, even though FDA equivalence is irrelevant to patent law because it involves
fundamentally different inquiries.").
193. See, e.g., Upjohn Co. v. Mova Pharm. Corp., 31 F. Supp. 2d 211, 215 n.2 (D.P.R.
1998) ("MOVA's admission of bioequivalence is not an admission of infringement under the
doctrine of equivalents. They are two distinct concepts."), aff'd in part, rev'd in part, 225 F.3d
1306 (Fed. Cir. 2000).
194. Abbott, 566 F.3d at 1298 ("Bioequivalency is a regulatory and medical concern
aimed at establishing that two compounds are effectively the same for pharmaceutical
purposes.").
195. Id.
196. Id. ("While bioequivalency may be relevant to the function prong of the function-
way-result test, bioequivalency and equivalent infringement are different inquiries. ... Differ-
ent attributes of a given product may thus be relevant to bioequivalency but not equivalent
infringement, and vice versa.").
197. See Abbott Labs. v. Sandoz, Inc., 486 F. Supp. 2d 767, 776 (N.D. Ill. 2007) ("If
bioequivalency meant per se infringement, no alternative to a patented medicine could ever be
offered to the public during the life of a patent.").
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particularly when aided by the input of independent experts, have the poten-
tial to inform courts making decisions about similarity of biologics in the
context of patent infringement, an entirely separate area. For example, the
argument could be made that if a drug is sufficiently similar to a pioneer that
it can use the accelerated pathway, this similarity should preclude its patent-
ability altogether. Conversely, if the FDA were to find that a junior biologic
was not highly similar, this finding could at least serve as a thumb on the
scale in determining non-equivalence.
Another area in which FDA analyses could influence patent-related de-
cisions concerns the use of postmarket safety or clinical data, because much
information about a biologic's effects only becomes available once patients
have widely used the drug. For applications filed before March 16, 2013,198
however, obviousness is measured from the time of the invention, so
postmarket safety data would likely be irrelevant to the obviousness in-
quiry-and this is unlikely to change when the time for measuring obvi-
ousness shifts to the filing date. It is not clear why postmarket safety data
could not be used for analyses of equivalence though, particularly when the
analysis focuses upon the "function" prong, since the doctrine of equivalents
has no evident timing requirement. If these data were permissible, an alleged
infringer could produce postmarket information to show functional differ-
ences in his product and consequently avoid a finding of equivalence.
E. Making the Decisions: Choices for Manufacturers
The above discussion highlights significant regulatory and patenting
concerns facing the manufacturers of biologic therapeutics. As these organi-
zations decide where and how to allocate their research and development
resources, however, other concerns are also pertinent and worth mentioning.
From an economic perspective, the development of biologics and bi-
osimilars may be a questionable investment. It represents an enormous in-
vestment of time and money, yet this investment may only yield diminishing
returns.'99 Although Humira, Enbrel, and Remicade have achieved signifi-
cant market presence and enormous financial returns, there are other TNFd
inhibitors that have not attained their clout-yet.200 Thus, development of
more TNFd inhibitors represents a gamble: a roll of the dice to yield a
198. The America Invents Act revision of 35 U.S.C. § 103 changes the time of obvi-
ousness inquiry to the time that the application was filed, taking effect for applications filed
after March 16, 2013. Leahy-Smith America Invents Act, Pub. L. No. 112-29, § 3(c), 125 Stat.
284 (2011).
199. See, e.g., McCamish, supra note 98, at 212. ("[Iln order to be viable as a business, a
[biosimilar] sponsor must also ensure their development is efficient by receiving product ap-
proval in a timely manner and with lower costs than those required for development of a novel
agent.").
200. For example, certolizumab pegol and golimumab, described in Aaltonen et al.,
supra note 37, at 11.
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Humira clearly justifies the investment, but this kind of success cannot likely
be predicted from the outset. This success heavily depends on another factor:
decision making on the part of physicians, who must choose to prescribe one
drug over another. Because doctors consider the efficacy, cost, safety, and
any special advantages of any particular drug, 21' it may be worthwhile for
manufacturers to invest in comparative effectiveness research. These eco-
nomic concerns should not necessarily constitute deal breakers. Even when
several similar biologics are available, the TNFA inhibitors demonstrate that
multiple members of one family may prove individually quite lucrative, par-
ticularly when the target disease affects great numbers of the population, and
the duration of illness is substantial.
For pharmaceutical manufacturers concerned with civic or social re-
sponsibility, it is also important to consider the impact of biologic and bi-
osimilar development on society at large. In particular, biosimilars exist to
treat the same mechanisms as preexisting pioneer drugs, though presumably
at lower cost. 202 Accordingly, their function is largely redundant, and a com-
parable argument can be made even for the similar-impact biologics. Crea-
tion of multiple TNFd inhibitors may preclude development of other useful
means of treating the target disease. In the etiology of RA, although TNF6-
TNFR signaling is an important player, it is by no means the only one, 2113 and
other molecules cause the inflammation characteristic of RA. 204 Thus, one
reasonable alternative strategy for pharmaceutical manufacturers is to pursue
drugs against other targets in the same compromised molecular pathway, if
applicable. In the case of RA, biological therapeutics have been developed
against such targets. 2115
Further, when pharmaceutical manufacturers expend their efforts to de-
velop similar drugs for common diseases, they divert human and financial
resources away from other socially useful avenues, such as developing treat-
ments for other diseases where the market is less saturated with competition.
This allocation of resources precludes the development of drugs for other
diseases, when that development would be less lucrative for the manufactur-
201. See Philip J. Mohler, New Drugs: How to Decide Which Ones to Prescribe, 13 FAM.
PRACTICE MGMT. 33, 34 (2006), available at http://www.aafp.org/fpm/2006/0600/p33.html
("Scrutinize new drugs that end with XL, CR, ER, SR or XR. Does the drug offer clinically
relevant new efficacy, safety or adherence benefits, or is it simply a 'me too' product?").
202. See Liang, supra note 7, at 416 (arguing that biosimilars will primarily be of interest
to those with financial constraints, as generics). However, if they are introduced only after
expiry of the reference drug patent and its market monopoly, it is not clear why the price of
one should differ from the price of the other.
203. See Sandeep K. Agarwal, Biologic Agents in Rheumatoid Arthritis: An Update for
Managed Care Professionals, 17 J. MANAGED CARE PHARMACY (SuPi.) S14 (2011), available
at http://www.amcp.org/WorkArea/DownloadAsset.aspx?id= 13697.
204. See id. at S14 (noting the roles of interleukins-1 and -6 and various proteases).
205. See id. at S16 (describing rituximab, a B-cell inactivating antibody, and tocilizumab,
an antibody against the interleukin-6 receptor). Rituximab is actually gaining popularity as a
backup treatment when other TNF6i inhibitor therapy fails.
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ers. For example, many people suffer from "orphan" diseases, for which no
effective drug has yet been developed, and they would greatly benefit from
pharma's investment. 206 Finally, others have worried about possible harm
posed by biosimilar drugs to especially vulnerable populations. 2 017 While
these concerns are valid, it is not apparent that they pertain to biosimilars
more than they would pertain to any drug that treats a serious disease.
Perhaps the strongest argument in favor of focusing upon similar-impact
biologic development is that when a great number of persons suffer from the
same disease, the need for a cure is proportionately large. Given the physio-
logical variability of these patients, a banquet of similar treatment options
may be extremely valuable. The TNF6 inhibitor data illustrate that many
patients may be unresponsive to one of the drugs, and the cited studies sug-
gest that patients are likely to derive a very strong health benefit from being
able to switch between available similar therapeutics, if one performs better
for them personally or has fewer attendant side effects.
A final consideration is that a heightened research focus on similar mol-
ecules may advance knowledge in the relevant field, but at the expense of
more novel, non-translational studies. Yet the types of different clinical ef-
fects described above observed for similar biologics do illustrate the nature
of biological complexity, and the commercial availability of these drugs
spurs research by interested clinicians and academics.
CONCLUSION
Despite the risks described above, it seems certain that many pharma-
ceutical manufacturers will opt to invest in developing similar biologics or
biosimilar therapeutics. Increased awareness of and attention to the scien-
tific, regulatory, and legal challenges facing their products is certain to help
these companies achieve the greatest return on their investment. Ultimately,
these efforts will redound to the benefit of patients anxious for relief.
206. See George J. Brewer, Drug Development for Orphan Diseases in the Context of
Personalized Medicine, 154 TRANSLATIONAL Ri's. 314, 314 (2009). Brewer notes that a drug
must service at least 200,000 patients in order for the manufacturer to turn a profit.
207. See Liang, supra note 7, at 416 (arguing that, due to their capability to treat serious
diseases, harm resulting from their unknown and unpredictable effects can fall disproportion-
ately on those with the greatest health concerns). For each disease cited, there are other availa-
ble drugs, each with their own attendant risks, which may be greater than any risk posed by a
biosimilar.
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